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ABSTRACT 
 
Candida krusei is an agent of opportunistic fungal infections, presenting intrinsic 
resistance to one of the first line therapy antifungals, fluconazole. It is also considered 
an emerging pathogen specially associated with patients presenting hematological 
malignancies. The hypothesis of an outbreak was considered due to the consecutive 
isolation of C. krusei strains from different patients staying in the Neutropenic Unit of 
hospital S. João, Porto, Portugal, within only a two month period. Candida krusei strains 
were also collected from the room´s surfaces, such as bed and bedside table. From one 
of the patients it was available a C. krusei isolate recovered two years before this 
episode, since this patient had a long history of admission to the hospital S. João. The 
hypothesis of an outbreak was excluded, after comparing the mitochondrial DNA 
restriction profiles using restriction endonuclease analysis: the C. krusei isolates from 
the different patients presented distinct molecular typing patterns. Candida krusei 
strains recovered from the same patient and from its respective bedside table or bed 
presented the same typing pattern. Although the hypothesis of an outbreak was 
excluded this work represented a landmark in the implementation of hygiene measures 
among the health care workers when dealing with the patients and in the maintenance 
of the surrounding environment of the patients.  
 From one of the patients involved in the hypothetical outbreak, a leukemia 
patient, several C. krusei isolates were recovered from different biological products, 
therefore he was prescribed voriconazole therapy. The first isolates, recovered before 
the voriconazole therapy, presented a susceptible phenotype but after three weeks of 
voriconazole therapy, resistant isolates to voriconazole were recovered. After 
performing the molecular typing of the isolates using restriction endonuclease analysis 
and random amplified polymorphic DNA analysis, it was proved the acquisition of 
resistance to voriconazole in vivo. The first susceptible C. krusei isolates presented the 
same molecular typing pattern than the latter resistant C. krusei isolates. Moreover, the 
acquisition of resistance in vivo was replicated by incubating one of these susceptible 
C. krusei isolates with a sub-inhibitory concentration of voriconazole. The aim of the 
work was accomplished since a minimal inhibitory concentration of 4 g/ml was 
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achieved after only 5 day of exposure to voriconazole, which was maintained stable 
even after withdrawn of the antifungal.  
 Another case with common characteristics was studied: a patient submitted to a 
kidney transplant was diagnosed candiduria due to C. krusei, and therefore began 
treatment with voriconazole. Although not usually considered a risk situation, after the 
determination of the susceptibility profile we were faced with two resistant isolates 
recovered during voriconazole therapy. The C. krusei isolates recovered before and 
after voriconazole therapy ended presented a susceptible phenotype. Moreover, the 
transient acquisition of resistance in vivo was confirmed: all the clinical isolates 
presented similar amplification patterns after their genotyping by PCR amplification of 
the intergenic repeat-PCR (CKRS-1) sequence. It was also evaluated how voriconazole 
at low concentrations (similar to the concentration achieved in the bladder) could 
influence the susceptibility profile of eight independent clinical strains susceptible to 
voriconazole from different backgrounds. Therefore, the acquisition of resistance in vivo 
was successfully reproduced in vitro.  
 At this point, the associated mechanisms of resistance of all the previously 
referred resistant strains were evaluated. Different approaches were used: a functional 
assay, using the efflux pump blocker Tacrolimus (FK506), and molecular assays, such 
as the quantification of gene expression and nucleotide sequencing. A synergistic effect 
was registered in the presence of Tacrolimus and voriconazole in both the microdilution 
assay and the test disk assay. The quantification of resistance gene expression showed 
that ABC1 gene was significantly overexpressed in the majority of the C. krusei strains 
induced both in vivo and in vitro in the two clinical cases. ABC2 gene presented no 
significant gene expression alteration in the resistant C. krusei strains therefore played 
a minor role in conferring resistance. The only exception was one of the strains 
obtained after the incubation in vitro with low concentrations of voriconazole which 
presented a sixteen fold increase in ABC2 gene expression. Overall, the different 
clinical isolates incubated in vitro with very small concentrations of voriconazole 
developed different ABC1 and ERG11 gene expression profiles, and different 
alterations in ERG11 gene nucleotide sequence. ERG11 gene sequencing showed 
different types of mutations: several heterozygous alterations at positions T1389T/C 
ABSTRACT 
 
- xxvii - 
 
and C642C/T, corresponding to a synonymous mutation and heterozygous alterations 
resulting in non-synonymous single nucleotide polymorphisms at positions G364T/G 
(AlaSer) and T418T/C (TyrHis). Since these alterations were found in the 
susceptible and resistant C. krusei strains they are not directly associated to 
voriconazole resistance. The most important alteration described was the homozygous 
missense mutation, at position T418C, in different resistant C. krusei strains yielding a 
TyrHis amino acid change. Therefore, this mutation was associated to voriconazole 
resistance in those strains. Due to the lack of information concerning the C. krusei 
genome most probably other mechanism of resistance are yet to uncover.  
 Overall this work highlights the relevance of the ATP-dependent efflux pumps 
activity, namely Abc1p, in voriconazole antifungal resistance and the description of new 
mutations in ERG11 gene among resistant C. krusei clinical isolates.  
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RESUMO 
 
 Candida krusei é um agente patogénico relacionado com infeções fúngicas 
oportunistas, apresentando resistência intrínseca a um dos fármacos mais utilizados 
em terapia antifúngica, o fluconazole. Candida krusei é considerado um agente 
emergente sendo frequentemente isolado de doentes com doença hematológica. Foi 
colocada a hipótese de ocorrência de um surto devido ao isolamento consecutivo de 
várias estirpes de C. krusei de diferentes doentes internados na unidade de doentes 
neutropénicos do Hospital de S. João, Porto, Portugal, durante um período de 2 meses. 
Estirpes de C. krusei foram também isoladas das respetivas cama ou mesa-de-
cabeceira dos doentes. Foi ainda incluída neste estudo uma estirpe isolada de um dos 
doentes, dois anos antes, uma vez que este apresentava um longo historial de 
internamento no Hospital de S. João. A hipótese de surto foi excluída após a análise 
comparativa dos perfis de restrição de DNA mitocondrial através da técnica de 
“restriction endonuclease analysis”, uma vez que isolados clínicos de C. krusei de 
diferentes doentes apresentavam também padrões de restrição molecular distintos. Por 
outro lado, os isolados clínicos do mesmo doente e da respetiva cama ou mesa-de-
cabeceira apresentavam o mesmo padrão de restrição molecular. Mesmo tendo sido 
excluída a hipótese de surto, o presente trabalho representa uma chamada de atenção 
para a implementação de medidas de higiene rigorosas entre os profissionais de saúde. 
Estes cuidados devem ser considerados não só na manipulação de doentes mas 
também na manutenção de um ambiente hospitalar adequado e seguro à permanência 
de doentes imunocomprometidos sem correrem riscos de infeção. 
 De um dos doentes envolvido no hipotético surto, um doente com leucemia, 
vários isolados clínicos de C. krusei foram obtidos a partir de diferentes produtos 
biológicos, pelo que iniciou tratamento com voriconazole. Os primeiros isolados clínicos 
obtidos antes da terapia antifúngica apresentavam um fenótipo suscetível, mas após 3 
semanas de terapia, foram detetados isolados resistentes ao voriconazole. Após a 
tipagem molecular dos diferentes isolados, recorrendo às técnicas de “restriction 
endonuclease analysis” e “random amplified polymorphic DNA”, verificou-se que os 
primeiros isolados suscetíveis de C. krusei apresentavam o mesmo padrão molecular 
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que os isolados resistentes obtidos posteriormente. Desta forma, confirmou-se a 
aquisição de resistência in vivo. Por outro lado, pretendeu-se mimetizar in vitro a 
aquisição de resistência ao voriconazole in vivo por incubação de uma estirpe 
suscetível isolada desse mesmo doente, com uma concentração sub-inibitória de 
voriconazole. O objetivo foi alcançado uma vez que após 5 dias de incubação com o 
antifúngico as estirpes apresentavam uma concentração inibitória mínima ao 
voriconazole de 4 g/ml. Mesmo após a remoção do antifúngico a estirpe manteve o 
fenótipo resistente.  
 Outro caso clínico com alguns aspectos em comum foi também estudado: foi 
diagnosticada candiduria por C. krusei num doente submetido a transplante de rim. O 
doente foi submetido a terapia antifúngica com voriconazole. A candiduria não é 
normalmente considerada uma situação de risco mas após avaliação do perfil de 
suscetibilidade verificou-se a existência de isolados de C. krusei resistentes ao 
voriconazole. Os isolados clínicos obtidos antes e depois da terapia antifúngica 
apresentavam fenótipo suscetível enquanto os isolados obtidos durante a terapia 
antifúngica apresentavam um fenótipo resistente. Comprovou-se a aquisição transitória 
de resistência in vivo: após a tipagem dos vários isolados clínicos por amplificação por 
PCR da sequência repetitiva intergénica (CKRS-1) verificou-se que estes 
apresentavam padrões moleculares semelhantes. Também se pretendeu avaliar o 
efeito da presença de uma dose mínima de voriconazole (semelhante à dose atingida 
na bexiga) no perfil de suscetibilidade de oito isolados clínicos suscetíveis de C. krusei 
provenientes de diferentes origens. Desta forma, a aquisição de resistência in vivo foi 
mimetizada in vitro. 
 Nesta fase, pretendeu-se estudar os mecanismos de resistência nas estirpes de 
C. krusei incluídas neste estudo. Diferentes abordagens foram realizadas: ensaios 
funcionais usando um bloqueador de bombas de efluxo, e estudos moleculares tais 
como a quantificação da expressão de genes associados a resistência e sequenciação 
nucleotídica. Foi registado um efeito sinérgico na presença do tacrolimus (FK506) e 
voriconazole quer nos ensaios de microdiluição e nos ensaios de difusão em disco. A 
quantificação da expressão dos genes de resistência mostrou que o gene ABC1 é 
significativamente sobre-expresso na maioria das estirpes de C. krusei induzidas in 
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vivo em ambos os casos clínicos e in vitro. O gene ABC2 não apresenta uma variação 
significativa na expressão em estirpes resistentes pelo que não será um gene relevante 
na resistência ao voriconazole. A única exceção foi uma das estirpes obtidas após 
incubação com concentração baixa de VRC que apresentou um aumento de 16x na 
expressão do gene ABC2. No geral, os diferentes isolados clínicos incubados in vitro 
com concentração baixa de voriconazole desenvolveram diferentes perfis de expressão 
dos genes ABC1 e ERG11 e diferentes alterações na sequência nucleotídica do gene 
ERG11. A sequenciação do gene ERG11 levou à deteção de diferentes tipos de 
alterações na sua sequência nucleotídica: alterações heterozigóticas sinonimas nas 
posições T1389T/C e C642C/T e alterações heterozigóticas não-sinonimas nas 
posições G364T/G (AlaSer) e T418T/C (TyrHis). Uma vez que estas alterações 
foram encontradas em estirpes suscetíveis e resistentes não foram nestes casos 
associadas a resistência ao voriconazole. No entanto, algumas estirpes resistentes de 
C. krusei apresentaram uma mutação “missense” homozigótica na posição T418C 
(TyrHis), pelo que esta mutação está associada a resistência. Devido à falta de 
informação relativamente ao genoma de C. krusei, outros mecanismos de resistência 
ainda não descritos podem estar presentes nestas estirpes.      
 Em conclusão, este trabalho salienta a importância da atividade de bombas de 
efluxo dependentes de ATP, nomeadamente Abc1p, na resistência ao voriconazole e a 
descrição de novas mutações no gene ERG11 em estirpes clinicas de C. krusei 
resistentes aos azoles. 
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“As grandes ideias surgem da observação dos pequenos detalhes.” 
Augusto Cury; médico psiquiatra, psicoterapeuta e escritor. 1958 
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AIMS OF THE STUDY 
The aims of the present work were to genotype C. krusei strains from different 
sources and to clarify the molecular mechanisms of resistance to voriconazole in C. 
krusei strains. Susceptibility profile evaluation and molecular studies were performed in 
order to understand the overall process of acquisition and development of resistance 
both in vivo and in vitro.  
 
Overall, the global aims were: 
i. Identification and genotyping of C. krusei clinical isolates; 
ii. Determination of the susceptibility profile of C. krusei clinical isolates to different 
classes of antifungals; 
iii. Understand the evolution of the susceptibility profile in vivo, namely, the acquisition 
of antifungal resistance; 
iv. Replicate in vitro the acquisition of resistance in vivo, in order to mimic the clinical 
conditions concerning the antifungal therapeutic; 
v. Understand which mechanisms of resistance were present in the C. krusei strains 
involved in the study. 
vii. Establish the importance of efflux activity in antifungal resistance.  
viii. Search for point mutations or heterozygous polymorphisms in the target gene 
ERG11. 
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OUTLINE OF THE THESIS 
 
 The present work is divided in chapters, which include the different works 
presented throughout the years in international conferences as poster presentations or 
abstracts published online and as published manuscripts in international indexed 
journals.  
 
Chapter I includes the aims of the work and an explanation of the structure of 
the thesis, in order to facilitate the reading and understanding of the overall work herein 
presented.  
Chapter II refers to the introduction section. After a large survey throughout the 
literature in the field, introduction presents the most important facts published in the last 
decades related to the present work. It constitutes a theoretical base to understand and 
discuss the work presented in the following chapters.  
Chapter III includes the first work published in an international indexed journal. It 
describes the case of several patients with candidiasis by C. krusei in the Neutropenic 
Unit of Hospital S. João, within a short period of time. The hypothesis of occurrence of 
an outbreak was evaluated. Fortunately, that hypothesis was discarded but another 
serious situation was encountered in one of the patients studied: the acquisition of 
resistance to voriconazole in vivo. 
Chapter IV involves two different works but with the same aims: the study of the 
acquisition of resistance in vivo and in vitro. The first case, also already published in an 
international journal, describes a leukemia patient with several clinical isolates of C. 
krusei recovered during a long period of voriconazole treatment. The second case is a 
patient submitted to a kidney transplant, diagnosed with candiduria and also submitted 
to voriconazole treatment but for a shorter period of time. In this case, C. krusei isolates 
were recovered before, during and after antifungal therapy. This work is submitted for 
publication.  
Chapter V includes an overall discussion of the different works presented in the 
two previous chapters. General conclusions are presented in this chapter. 
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Chapter VI describes the future perspectives, i. e., intends to point new 
directions based on the current findings for a more profound study of the molecular 
mechanisms of resistance. 
Chapter VII lists the bibliography accessed throughout the development of the 
work and thesis. 
Chapter VIII includes the publications associated to the present work.  
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“Existem muitas hipóteses em ciência que estão erradas.  
Isso é perfeitamente aceitável, elas são a abertura para achar as que estão certas”. 
Carl Sagan, astrobiólogo, astrônomo, astrofísico, cosmólogo, escritor e divulgador científico. 
1934- 1996. 
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The genus Candida 
 
 The genus Candida was first discovered by Langenbeck in 1839 from buccal 
aphthae in a patient with typhus [1]. The Candida name has its origin in the ancient 
Rome tradition of a Candidatus, i. e., a candidate for public office to dress in white. The 
genus Candida comprises heterogeneous anamorphic yeasts, which are able to grow in 
three different morphologies: yeast, pseudohyphae and hyphae. They are ubiquitous 
and opportunistic commensal organisms of the human host. There are approximately 
200 species of Candida, however only a small number is pathogenic to the human host, 
since more than 65% do not grow at the human body temperature, 37ºC [2]. Candida 
species are mostly isolated from the genital area, oral cavity, gastrointestinal tract, 
blood, normally sterile body fluids, urine, respiratory tract, skin and soft tissue [3]. When 
there is a shift in the balance of the fungus-host interaction, in favor of the fungus, an 
infection process can occur, ultimately leading to a disease condition. The classification 
of fungal infections is dependent on the degree of tissue involvement and the mode of 
entry of the pathogen: (i) superficial infections are localized to the skin, hair, and nails 
and are the most common yeast cell’s infections; (ii) subcutaneous infections are 
confined to the dermis, subcutaneous tissue, or adjacent structures; and (iii) systemic 
infections are confined to deep infection of the internal organs, entering the blood 
stream and causing disseminated infection. The systemic infections usually occur only 
in immunocompromised patients. 
 Complementing functional and phenotypic studies, molecular studies of Candida 
spp. have increased exponentially in the last decades due to the sequencing of several 
genomes of pathogenic yeast [4-6]. This fact allowed the scientific community involved 
in the yeast research to uncover the different mechanism of interaction between host 
and pathogen, to describe in detail several molecular mechanisms of resistance to 
antifungals or the development of molecular tools to manipulate pathogenic yeasts 
genomes.   
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Candida krusei  
 Candida krusei was first described by Castellani in 1910 as Sacharomyces 
krusei. Several other names were proposed: Endomyces krusei in 1912, Monilia krusei 
in 1913, by Chalmers and eighteen other synonyms were proposed before Berkhout -
renamed it in 1923 as Candida krusei [7-8]. In 1960, Issatchenkia was proposed by 
Kudryavtsev for the ascosporic state of C. krusei. This genus was characterized by the 
formation of spherical, possibly roughened ascosporous formed in a persistent ascus. 
Kurtzman et al in 1980 assigned additional species to this genus as Issatchenkia 
orientalis [9]. Candida krusei is the asexual (anamorphic) form, not producing 
ascosporous and considered the imperfect form, while Issatchenkia orientalis or Pichia 
kudriavzevii is the teleomorph (non-spore) form with a complete meiotic sexual cycle, 
considered as the perfect form [9]. The transformation between these 2 forms is a 
complicated matter and usually depends on the environmental conditions [10, 11]. 
Candida krusei as it will be referred from this point is usually found in 2 basic 
morphological forms (dimorphism): yeast and pseudohyphae [12]. Both are frequently 
present in growing cultures and are not easily separated. The pseudohyphae state 
makes C. krusei invasive conversely to the non-invasive yeast form [13].   
 Candida krusei displays 8 chromosomes with a total size of about 20Mb 
estimated by pulsed- field gel electrophoresis (PFGE) [14]. It is likely diploid, as it was 
already demonstrated in different studies: C. krusei is heterozygous at a URA gene [15], 
rDNA and TUB2 probes hybridized to two chromosomes bands [14] and the presence 
of 2 alleles for ERG11 gene were described [16]. Considering its genetic traits, C. krusei 
is more closely related to Candida glabrata and Sacharomyces cerevisiae than to 
Candida albicans. For example, C. krusei translates the codon CUG as leucine, 
similarly to C. glabrata and S. cerevisiae [17, 18]. 
 Similar to other Candida species, C. krusei presents several virulence attributes, 
namely adherence to host surfaces, production of phospholipases and proteinases, 
antigenic variability, dimorphic transition (yeast to pseudohypha), phenotypic switching 
or capability of switching among different cells phenotype and modulation of the host’s 
immune response [13]. Nevertheless, several virulence comparative studies performed 
among Candida species had concluded that C. krusei is relatively less virulent than 
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other commonly pathogenic Candida spp. such as C. albicans [19-22]. 
  The study of C. krusei is always a challenge since the available information 
concerning this species is scarce when compared to other pathogenic yeasts.  
 
Epidemiology of Candidiasis  
 In the end of the 20th century a dramatic increase in mortality rates due to 
mycoses was registered in the United States: from 1557 deaths in 1980 to 6534 deaths 
in 1997 [23]. These deaths were mostly related to Candida, Aspergillus and 
Cryptococcus spp infections, being Candida spp in the top of list as the most important 
cause of opportunistic mycoses worldwide [24]. Candida species are the fourth leading 
cause of healthcare related bloodstream infections (BSI) in the United States 
representing for 8% to 10% of all BSI acquired in the hospital [25-28]. Invasive Candida 
infections are usually healthcare-associated infections and may be either nosocomial 
(onset after 48h of hospitalization) or community-onset (occurring within 2 days of 
admission) [24, 29, 30]. The most frequently isolated pathogenic species of Candida 
spp., accounting for more than 90% of invasive candidiasis (IC) in humans are C. 
albicans, C. parapsilosis, C. glabrata, C. tropicalis and C. krusei [24, 31-33]. A study by 
Pfaller and Diekema showed that the distribution of species responsible for invasive 
infections has changed in the last years: the rate of isolation of C. albicans decreased 
from 73.3% in the period 1997-1998 to 62.3% in 2003 [3]. Also, a more recent study by 
Pfaller et al, 2012 involving 23 medical centers in the USA and 2 in Canada, registered 
a new distribution of Candida species: C. albicans (42.1%), C. glabrata (26.7%), C. 
parapsilosis (15.9%), C. tropicalis (8.7%), and C. krusei (3.4%) [33]. Overall, the 
proportion of candidemia caused by non-albicans Candida spp. (57.9%) was higher 
than that caused by C. albicans (42.1%) solely [33]. This alteration in species 
distribution can be associated with different factors such as the reduced susceptibility of 
Candida species to fluconazole (FLC) due to its extensive use throughout the 1990s, 
the increase in the number of immunocompromised patients vulnerable to infection with 
less virulent species of Candida or even as a consequence of the recent progress in 
isolation and identification methods for Candida species [34].  
 In Europe, according to the European Confederation of Medical Mycology 
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(ECMM) survey presented in 2004, C. albicans was responsible for more than one-half 
of the Candida infection cases in all the patient populations, except in patients with 
hematological malignancies. In these patients, C. albicans was isolated in 35% of the 
cases, C. tropicalis in 17% and other Candida species in 24%, with C. krusei involved in 
12% of these cases [35]. Similar to what happens in the United States, Candida species 
frequency varies among different European countries [35]. The first Portuguese study 
performed at a large Portuguese University Hospital, Hospital S. João, EPE, involved 
117 patients with the diagnosis of fungaemia, therefore not limited to infection by 
Candida spp. Yeasts were the fourth most common agent isolated from blood. Candida 
albicans ranked on the top of the list corresponding to 35% of the yeast isolates, 
followed by C. parapsilosis (25.6%), C. tropicalis (12.8%), C. neoformans (10.3%) and 
C. glabrata (7.7%) [36]. 
 The risk factors associated to infection by Candida spp have been well 
established and have not changed substantially in the past 2 decades (detailed in 
Table1). 
 
Table 1. Risk factors predisposing individuals to disseminated candidiasis 
 
Risk factor References 
Cancer chemotherapy 37; 38 
Prior colonization and the use of intravenous catheters 36; 39; 40 
Therapy with broad-spectrum antimicrobial agents 38; 39; 41; 
Metabolic dysfunction such as Diabetes 42; 43 
Immunosuppression (including neutropenia) 44-46 
Mucosal colonization by Candida spp 47 
Total parenteral nutrition (TPN) 36, 48; 49 
Surgery (including organ transplantation 36; 47; 49  
Renal failure or hemodialysis 47; 49-53 
 
Additionally, patients with hematological malignancies are more prone to BSI caused by 
non-albicans Candida species, namely, C. tropicalis, C. parapsilosis and C. krusei [44, 
45]. 
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 According to the ECMM survey, candidemia is associated to a high mortality rate 
(38%) [51, 54, 55]. Although less frequently isolated, C. krusei, C. glabrata and C. 
tropicalis BSIs, appeared particularly severe, with an unfavorable outcome in more than 
40% of the patients [51]. In the Portuguese study, the mortality rate associated with 
fungemia was 39.3%; the highest values were found in patients yielding C. glabrata 
(78%), C. tropicalis (53%) and C. albicans (46%) infection. Seventy-five per cent of the 
fungemia episodes were nosocomial, with 48% mortality rate [36]. The high crude 
mortality rate of BSIs caused by these non-albicans species may be due to their 
occurrence in patients with underlying life-threatening conditions. Death has been 
considered to be directly attributable to candidemia in 8% of cancer patients [56] and 
20–31% of patients staying in intensive care units (ICU) [57-59]. This makes the study 
of these non-albicans Candida species such an important issue. 
 
 Besides candidemia the occurrence of candiduria is also observed in 
hospitalized patients. A survey of urine cultures obtained from hospitalized patients 
throughout European hospitals, showed that Candida species were the third most 
common organism isolated from urine after Escherichia coli and Enterococcus species 
[60]. Most of the fungal infections of the urinary tract are due to C. albicans, accounting 
for 50% to 70% of the isolates [60-63]. C. glabrata and C. tropicalis are usually the 
second most common cause of urinary tract infections [63-65]. Other Candida species 
such as C. parapsilosis, 1% to 7%, or C. krusei, 1% to 2% are less commonly found in 
the urine [64]. Although few studies are available, several risk factors were already 
described: urinary drainage devices, urinary tract obstruction, surgery or 
instrumentation, diabetes mellitus, antibiotic use and older age [61, 62, 66]. They also 
concluded that these risk factors are also valid not only for hospitalized patients but also 
for the community in general. There is the general question if candiduria can lead to 
candidemia. In a large prospective surveillance study, only 7 out of 530 candiduric 
patients, corresponding to 1.3%, developed candidemia [61]. In another study 
performed in an ICU setting from France, only 5 patients developed candidemia from a 
total of 233 patients with candiduria, due to the same species 2 to 15 days later [67].  
However, other studies indicate candiduria as a well-established risk factor for IC which 
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in turn is associated with significant morbidity, mortality and cost in ICU patients [68, 
69]. Candida species cause urinary tract infection (UTI) by two different routes: the 
hematogenous route and the most common, the ascending route. The pathogenesis of 
ascending infection has not been studied in depth and the data are scarce [70]. For 
example, some studies show that the spread from the perineum into the bladder leads 
to colonization and the retrograde spread occurs into the collecting system of the kidney 
[71]. Also, the presence of an indwelling catheter allows for biofilm and fungus balls 
formation, i.e., mass of hyphae and yeast cells, and consequently the persistence of the 
organism in the host [70].  
 One of the largest concerns when dealing with a patient with candiduria is 
deciding whether this finding represents a contaminated urine sample, an organism 
colonizing the bladder and/or catheter, or an infection of the urinary tract. Additionally, 
candiduria may be a manifestation of candidemia rather than UTI; therefore it is 
important to understand the meaning of the presence of Candida in the urine [72]. Urine 
analysis and culture are the first laboratory studies that should be performed. The 
techniques routinely used in most clinical microbiology laboratories for the detection of 
bacteria are adequate for detecting yeasts in urine. The management of candiduria 
remains controversial, mainly due to clinicians’ uncertainties when to initiate antifungal 
therapy for candiduria [73-76]. Among the different classes of antifungal drugs none of 
them presents a perfect therapeutic outcome. Fluconazole (FLC) is normally the first 
line treatment option as it is excreted unchanged by the kidneys, ketoconazole (KTC) 
and itraconazole (ITC) are poorly excreted in the urine, voriconazole (VRC) and 
posaconazole (PSC) achieve minimal urinary excretion, amphotericin B (AMB B) 
presents high renal toxicity, leading to decreased glomerular filtration rate; all the 
echinocandins are extremely poorly glomerularly filtrated or tubularly secreted in vivo, 
as 2–3% of active drug is eliminated in the urine, resulting in subtherapeutic 
concentrations in the urine [77-80]. Nevertheless, some antifungal therapies present 
positive outcomes: there are observations about several successful outcomes for the 
treatment of symptomatic candiduria using caspofungin (CSF) [81]. Usually, FLC 
achieves 10-fold higher concentrations in the urine than in serum [75]. A single 400 mg 
dose of FLC leads a concentration in excess in the urine of 100 mg/ml in patients with 
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normal renal function [77]. Overall,  the treatment of candiduria involves many issues: 
asymptomatic candiduria should not be treated with antifungal agents, except in certain 
population at risk of candidemia, antifungal susceptibilities and concentrations of 
antifungal agents in the urine should be taken into account in the choice of the 
appropriate antifungal agent, the persistence of indwelling urinary catheters can 
interfere with the therapy and the maintenance of the obstruction in the urinary tract can 
interfere with the antifungal therapy efficacy. 
  
 The first case of C. krusei fungemia and systemic infection was described by 
Young et al in 1974, when isolated from a patient from the National Cancer Institute 
(Bethesda, MD, USA) [82]. Few studies have addressed solely the epidemiology of C. 
krusei in the latest century [12, 83]. Recently, the single study by Pfaller et al, 2008, 
addressed the global epidemiology of C. krusei alone: C. krusei ranked in fifth place 
among 22 different species of Candida, accounting for 3.3% of all candida spp. isolated 
in both Europe and North America [84]. In detail, isolation rates of C. krusei represented 
3.5% in the United States and 1.8% in Canada; the Eastern European countries 
presented the highest frequency of C. krusei isolation, namely, the Czech Republic, 
7.6%, Poland, 6.0% and Slovakia, 5.1%. Conversely in the Asia-Pacific region was 
1.3% and Latin America 1.7%. In some other countries the frequency of isolation was 
even lower: the Netherlands 0.5%, South Korea 0.3%, Taiwan 0.6%, Thailand 0.3%, 
and Ecuador 0.5% [84]. In the Portuguese epidemiological study only one isolate of C. 
krusei was registered [36].  
 The clinical services reporting the isolation of C. krusei from patient specimens 
include the hematology-oncology service, medical and surgical services, intensive care 
units (medical, surgical, and neonatal), dermatology services, obstetrics and 
gynecology services, urology services, and the outpatient services. Candida krusei is 
mostly frequent isolated among patients with hematologic malignancies than from 
patients with other pathological conditions combined and among blood and bone 
marrow transplant recipients [84-86]. In a more recent study by Pfaller et al 2012, the 
patients infected with C. krusei were frequently neutropenic (51.3%), recipients of an 
hematopoietic stem cell transplantation (19.4%) or suffering from a hematologic 
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malignancy (16.0%); another interesting fact is that 79.6% of the patients with C. krusei 
infection had received prior antifungal therapy [33].  
 
 Behind thousands and thousands of epidemiological studies worldwide, accurate 
and specific identification and characterization of yeast species have to be performed. 
Therefore, several different identification and typing methods have been developed and 
upgraded throughout the decades of yeast research.  
 
Identification and Typing Methods 
 In the microbiology laboratory routine, biochemical assays based on panels of 
sugar assimilation are the most commonly used techniques for yeast identification. In 
recent years, chromogenic agars and automated biochemical systems such as the API 
series and Vitek systems from bioMerieux or Auxacolor from Sanofi-Pasteur/ Biorad 
have been developed for yeast identification. Chromogenic and fluorogenic agars type 
medium incorporate compounds that when hydrolyzed by enzymes produced by yeast 
cells, form colored or fluorescent products, respectively [87]. These biochemical 
reactions allow the detection of mixtures of different yeasts species and their 
presumptive identification.  However, when the aim is to type different strains within 
specie, it is necessary to use more discriminatory techniques. In early years, traditional 
typing systems based on phenotype, such as serotype, biotype, phage-type or 
antibiogram, have been used. Later, when presenting extensive epidemiological 
surveillance studies, molecular methods overcame previously used phenotypic tests 
due to its higher discriminatory power [88, 89]. Moreover, DNA sequence differences 
are usually more stable than phenotypic differences [90, 91]. The specificity of the 
molecular methods has revealed the existence of new species among previously 
considered homogeneous species, such as C. bracariensis often identified as C. 
glabrata or C. dubliniensis originally identified as C. albicans [92-93]. The identification 
of epidemiologically related isolates, allows to the clinicians to locate the origin of an 
infecting agent in different situations: clarify transmission pathways in health care 
facilities related to health care associated outbreaks, recurrent infections or provide 
information concerning the population structure of the isolates. 
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 PCR amplification is undoubtedly the technique mostly used within the different 
molecular typing techniques due to its high sensitivity and quickness: PCR with specific 
primers at the genus or species level, multiplex PCR, PCR amplification and 
subsequent southern blot, PCR followed by restriction analysis of amplicons, nested 
PCR, Real Time PCR, PCR followed by nucleotide sequencing [94–97]. Different 
molecular typing methods have been applied to C. albicans, namely, multi-locus 
enzyme electrophoresis (MLEE) and multi-locus sequence typing (MLST), restriction 
enzyme analysis (REA), karyotype analysis and randomly amplified polymorphic DNA 
(RAPD) analysis (98-104). Nowadays, the analysis of sequence polymorphisms is the 
gold standard for strain typing and the MLST is the most used molecular technique. It 
has already been published for the most important and frequently isolated pathogenic 
Candida species: C. dubliniensis, C. tropicalis, C. parapsilosis, C. krusei and C. 
glabrata [100-104].  
 
 Restriction enzyme analysis (REA) has been described in the last decade as a 
valuable tool for Candida spp. characterization. The digestion of genomic DNA with 
specific restriction endonucleases has been widely used in several different techniques 
[105-107]. However, the differences between the nuclear DNA and the mitochondrial 
DNA (mtDNA) such as the mtDNA small size, the high number of mtDNA molecules by 
cell and one single mitochondrial karyotype in each wild dikaryotic isolate, has lead the 
use of mtDNA in yeast taxonomy to a top position [108]. Nevertheless, the different GC 
content of nuclear DNA (40%) vs. the mtDNA (20%) is the most important feature in this 
methodology. When total fungal DNA is digested with restriction enzymes that only 
recognize GC rich regions, as for example MspI, HaeIII, or HinfI all with 50% GC target 
site, the nuclear DNA is overdigested originating a high number of short fragments, that 
are not detected by conventional agarose gel electrophoresis. Conversely, the 
restriction of mtDNA will originate fragments with higher molecular weight and those will 
be the only ones detected in the electrophoresis gel. 
 REA of the mtDNA was first applied in the biotechnology industry in order to 
characterize yeast strains used for wine fermentation [109-110] and, more recently, to 
discriminate between Candida clinical strains [111-114]. The data obtained demonstrate 
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the relevance of using molecular genetics methods in many different areas, including 
taxonomic, ecological and clinical surveys. 
  
 In Random Amplified Polymorphic DNA (RAPD) analysis, genomic DNA is 
amplified at a low, non-stringent annealing temperatures (30–38ºC) with short arbitrary 
sequences of oligonucleotide (usually 10 nucleotides). These short primers target 
unspecific genomic sequences, such as sequence length polymorphisms in the genome, 
generating multiple PCR products of different electrophoretic mobility. When comparing 
strains within species, the RAPD fingerprints obtained are combinations of different 
numbers of amplicons with different sizes, since the number and positions of primer 
binding sites are unique to a particular strain [115-117]. Similarities in banding profiles 
among strains (i.e. the number and mobility) can be calculated and used to infer 
epidemiological relationships. When multiple primers are employed, the RAPD 
fingerprints are sufficiently sensitive to detect variation among isolates, being a typing 
technique with a high discriminatory power yielding feasible results. Despite being 
technically fast and simple, there are some disadvantages in RAPD analysis. The major 
drawback is its low intra-laboratory reproducibility. Small differences in PCR conditions, 
such as reagents, protocols and even the technical equipment, may affect binding of the 
primers. This problem is minimized when the protocol and reagents are carefully 
standardized. For this reason, the RAPD fingerprints of individual strains are generally 
specific to each laboratory but not interlaboratory. RAPDs can also be problematic 
because bands with the same electrophoretic mobility may not share the same 
sequence [118]. Nevertheless, for comparing the similarities among strains and 
developing fingerprints for molecular epidemiology, RAPD analyses have been widely 
applied to a large number of medical fungi [119- 122]. 
                                                                                                                             
 PCR-Based Amplification of the Species-Specific Repetitive Polymorphic 
Sequence CKRS-1 was developed by Carlotti et al, as a simple and fast PCR method to 
identify and fingerprint specifically C. krusei strains. The polymorphic species-specific 
repetitive sequence, designated as CKRS-1 (C. krusei repeated sequence 1) was first 
identified in the nontranscribed intergenic regions (IGRs) of rRNA genes in C. krusei 
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and it is used in this technique as the template sequence [111]. First, DNA probe CkF1, 
2 labeled with peroxide enzyme, was designed based on two cloned EcoRI restriction 
fragments, F1 and F2 which are polymorphic forms of the nontranscribed IGRs. Both F1 
and F2 contain the repeated sequence, CKRS-1 which is made up of eight and seven 
shorter tandemly repeated sequences of about 165 bp, respectively. This methodology 
conjugates both REA and PCR amplification in order to increase the discriminatory 
power of the typing technique. Additionally, it combines the identification and 
fingerprinting of C. krusei since specificity assays were performed with other Candida 
species and no amplification was detected [111]. Another advantage of combining REA 
with the specific probe CkF1, 2 is the high degree of resolution of the fragments. This 
improved the rapid comparison of patterns as the number of fragments to consider was 
lower than in direct REAs but the number and sizes were sufficiently varied [111]. Later, 
based on the same polymorphic region in C. krusei, new specific primers were 
designed, Arno1 and Arno2, for an even faster, reliable and sensitive typing of C. krusei 
strains, using only DNA amplification by PCR. With this technique, results were 
achieved in less than 6 h and allowed the simultaneous typing of the isolates. Besides, 
this method showed 100% typeability, more than 98% in vitro reproducibility and a 
discriminatory power of 1 [111].    
 
Several case reports of Candida spp. outbreaks involving the same strains have 
been described throughout the years, corroborated by the molecular identification and 
typing. However, in many cases those same strains might present different 
susceptibility profiles. Therefore, whether isolated from outbreaks or solely from 
patients, it is crucial to characterize the clinical isolates phenotype and understand their 
behavior towards the antifungal drugs.  
 
Antifungal therapy and susceptibility assays 
 
Different classes of antifungals with different mechanisms of action are available 
for the treatment of fungal infections, being the azoles the most used drugs. However, 
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the antifungal therapy is very limited due to biosafety problems, development of 
antifungal resistance, bioavailability and bioefficacy.  
There are 4 classes of antifungals available, divided according to their 
mechanism of action: the azoles, i. e., FLC, VRC, PSC; the polyenes, i. e., lipossomic 
and deoxicolate AMB B, nystatin; the echinocandins, i.e., CSF, micafungin (MCF), 
anidulafungin (AND) and the pyrimidine analogues, i. e., 5-Flucytosine (5-FC). 
Antifungal agents have different cellular targets, important for the growth and survival of 
fungal pathogens. Azoles and AMB B interfere with fungal sterol, echinocandins impair 
the cell wall structure and pyrimidine analogues interfere with nucleic acid metabolism 
and protein synthesis.  
 
 
Figure 1 – Antifungal drugs mechanisms of action.  Azoles antifungals inhibit the enzyme lanosterol 14α- 
demethylase, involved in the synthesis of ergosterol, a main component of the cell membrane. This 
inhibition leads to the production of toxic compounds altering cell membrane structure and permeability. 
Polyenes bind to ergosterol molecules forming pores in the membrane. Pyrimidine analogues induce the 
production of toxic compounds that interfere with the nucleic acid metabolism and consequently protein 
synthesis. Echinocandinds inhibit the enzyme β (1,3) – glucan synthase leading to alterations in the cell 
wall structure.  
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A recent study by Pfaller et al, 2012, showed that FLC was the most frequently 
administered antifungal agent (66.0%) followed by the echinocandins (55.1%) [33]. 
Neither VRC (7.8%) nor AMB B deoxycholate (2.3%) were used very often for the 
treatment of candidemia in the participating centers. Combination/sequential therapy, 
generally with an echinocandin and FLC were reported in 44.8% of patients with 
candidemia [33]. 
Antifungal activity may differ between different species of Candida, as is the 
case of C. krusei which is intrinsic resistant to FLC [123-125]. Candida krusei is 
considered a potentially multidrug-resistant (MDR) fungal pathogen, due to its 
susceptibility profile to different classes of antifungals: intrinsic resistance to FLC and 
decreased susceptibility to AMB and 5-FC [24, 126-130]. In the epidemiological study 
by Pfaller et al, all the isolates were considered clinically resistant to FLC and overall 
7.8% were resistant to VRC [84]. However, considerable differences in the susceptibility 
pattern to VRC were registered among the countries studied. In North America 92.3% of 
the isolates were susceptible to VRC while in Latin America only 74.8% were 
susceptible to VRC, comprising countries like Brazil 65.9%, Colombia 61.8% and 
Mexico 63.6% [84]. Conversely, susceptibility rates to VRC were extremely high in 
countries such as Australia 100%, Taiwan 94.7%, Thailand 100%, Belgium 97.3%, 
Germany 90.9%, The Netherlands 100%, Poland 98.4%, Portugal 96.1%, Slovakia  
90.1%, Switzerland 93.6%, Argentina 93.8%, Israel 94.7% and Canada 93.8% [84]. 
Considering the AMB and 5- FC susceptibility profiles, the global study corroborated 
results previously registered: decreased susceptibilities to AMB, i. e., 90% of the 
isolates were inhibited only for a MIC of 4 g/ml, and only 8% were considered 
susceptible to 5- FC for a MIC of 16 g/ml. Concerning the echinocandins, all C. krusei 
isolates were susceptible to CSF, AND and MCF at the CLSI breakpoints concentration 
of < 2 g/ml [84]. In another worldwide study, the SENTRY data, from 29 isolates of C. 
krusei tested, 3.5% of isolates were susceptible, 79.3 fell in the susceptible dose 
dependent range, and 17.2% were resistant to FLC [131]. In the same study, 100% of 
the 29 isolates were susceptible to AND and 97% to CSF; 93% were susceptible to 
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AMB and 93% susceptible to VRC. Only 3.4% were susceptible to 5-FC, which is a 
common characteristic of most studies reporting on C. krusei susceptibility [131].  
 It should also be stressed that, conversely to what would be expected, FLC 
exposure alone cannot be the only factor associated with an increase in infections 
caused by this species, since the increase in the prevalence of C. krusei predated the 
use of FLC in some institutions [132 – 134]. 
 
The Azoles 
 The target of the azole drugs is the cytochtome P450-dependent enzyme 
lanosterol 14α- demethylase - Erg11p, encoded by ERG11 gene. This enzyme 
promotes the sterol 14α-demethylation reaction in ergosterol biosynthesis [135-137]. 
Ergosterol is the main sterol in most yeast and fungi, indispensable component of 
cellular membranes and an irreplaceable requisite for cell proliferation. Azoles bind to 
the protein active site through an heme domain, containing a free nitrogen atom in the 
pyrrolic rings and the iron atom from heme group, impairing the activation of the oxygen 
atom and consequently the demethylation of lanosterol (removal of methyl group) [138-
139]. The fungistatic effect of azoles is not due to an impairment of ergosterol 
biosynthesis pathway but instead, due to the production and accumulation of 14- 
methylated toxic compounds in the yeast cells such as 14-methylergosta-8,24(28)-dien-
3,6-diol, ignasterol, or 4,4- dimethyl zymosterol, and other compounds such as eburicol, 
lanosterol, obtusifoliol,  14a-methyl-fecosterolobtusifoliol or 14a-methyl fecosterol, at the 
expense of ergosterol within the cell [137, 140]. The accumulation of the toxic 
compounds together with the lack of ergosterol, alters the function and fluidity of the 
plasmatic membrane [141]. Although all azoles bind to the 14α – demethylase enzyme 
inhibiting its activity, they differ in their binding affinity. This difference is responsible for 
their varying antifungal potency and varying spectrum of activity [142-145]. For 
example, the imidazole derivatives such as miconazole (MCZ) and ketoconazole (KTC), 
inhibit besides the 14α – demethylase enzyme, several membrane bound enzymes and 
membrane lipid biosynthesis; conversely the triazoles derivatives such as ITC and FLC 
exert their antifungal activity only by inhibition of the cytochrome P450 dependent 
Erg11p [145]. 
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One of the major advantages of using azoles when compared to AMB 
administration is their lower toxicity to the patients and oral and intravenous availability 
[146 - 147]. However, azole therapy can induce antifungal resistance in the pathogenic 
yeasts very rapidly, which might lead to an increasing in the frequency of infections 
[148-150]. On the other hand, some of the azoles such as FLC or ITC can interact with 
other drugs, namely benzodiazepines, cyclosporines, antihistamines, antibiotics or HIV 
protease inhibitors [151-153]. Another problem associated to the azole antifungal 
therapy is the homology between enzymes of the ergosterol biosynthesis pathway and 
the target enzymes of the cholesterol biosynthesis pathway in the liver cells of 
mammals, being therefore also toxic to the host in some extent. The newer azoles like 
VRC and PSC have been developed to overcome the limited efficacy of FLC against 
Aspergillus spp. and other moulds and to improve the absorption, tolerability, and drug 
interactions profile of ITC [154].  
 
Fluconazole (figure 1) is available in both, oral suspension, presenting good 
absorption rate and not affected by food or gastric pH and intravenous (IV) formulations. 
Fluconazole is the drug of election for first line antifungal treatment of clinically stable 
patients and for empirical treatment in cases of suspected disseminated candidiasis in 
febrile non-neutropenic patients in countries where the rate of resistance species like C. 
krusei and C. glabrata is below 10–15%. It has been effective in treating both superficial 
infections such as vaginal candidiasis, oropharyngeal and esophageal candidiasis. It is 
also recommended for prophylaxis in bone marrow transplant patients to decrease the 
development of disseminated candidiasis. Fluconazole spectrum of activity includes C. 
albicans, most strains of C. tropicalis, and C. parapsilosis; conversely, C. krusei is 
intrinsically resistant and C. glabrata demonstrates reduced susceptibility to FLC. 
Fluconazole is most often considered a yeast agent and not a mould agent.  
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Figure 2 – Fluconazole chemical structure. 
 
Voriconazole (figure 2) chemical structure is very similar to FLC, being the most 
significant difference the presence of an additional methyl group. It is available in both 
oral and IV formulations and is normally well tolerated. It is indicated for the primary 
treatment of aspergillosis, for salvage therapy of serious fungal infections due to 
Fusarium sp. and Scedosporium sp. (P. boydii) in patients refractory or intolerant to 
other therapies. Voriconazole presents a large spectrum of activity against Candida 
spp., including C. krusei and C. glabrata, intrinsically resistant to FLC. Importantly, VRC 
has been pointed out as a good alternative not only to FLC in the treatment of 
candidemia in the non-neutropenic patients, but also when the causative organism is 
resistant to other azole antifungal agents; also, in disseminated Candida skin infections 
or Candida infections of abdomen, kidney and bladder wall and in esophageal 
candidiasis [155]. The minimal inhibitory concentration (MIC) of VRC for C. albicans is 
usually 1 to 2 log lower than the MICs for FLC. However, some highly fluconazole-
resistant strains of C. glabrata may demonstrate higher MICs to VRC [156].  Besides 
Erg11p, VRC also inhibits 24 – methylene dihydro-lanosterol demethylase exerting 
increased activity against moulds. The action is often fungicidal for moulds, increasing 
the sensitivity of the fungus to oxygen-dependent microbicidal systems of the host. 
However, there have been some reports of increased incidence of infections with 
Zygomycetes in association with increased use of VRC [157, 158].  
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Figure 3 – Voriconazole chemical structure. 
 
 Posaconazole (Figure 3) is only available as an oral suspension. It was 
approved by the FDA for the prophylaxis of invasive Aspergillus and Candida spp. 
infections in high risk, severely immunocompromised patients older than 13 years old. 
The targeted patients include hematopoietic stem cell transplant recipients with graft vs. 
host disease and patients with hematologic malignancies with prolonged neutropenia; it 
is also recommended for the treatment of oropharyngeal candidiasis, including cases 
that are intolerant or refractory to ITC and/or FLC therapy [159-160]. Posaconazole has 
a broad spectrum of activity towards yeasts, filamentous and dimorphic fungi, namely 
Candida spp., Cryptococcus neoformans, Aspergillus spp., Rhizopus spp., Blastomyces 
dermatitidis, Histoplasma capsulatum, Coccidioides immitis, dermatophytes, and 
dematiaceous fungi. Posaconazole is less active in vitro against FLC resistance in 
Candida spp., especially C. glabrata and C. krusei. It presents lower nephrotoxicity, 
hepatic toxicity and ocular toxicity than other triazoles. Since it is metabolized in the 
liver, PSC has fewer effects on patients with renal impairment.  
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Figure 4 – Posaconazole chemical structure. 
 
The Polyenes 
The polyenes are amphipathic molecules, lipophilic and insoluble in water being 
the most known representatives AMB B (figure 4) and nystatin. AMB is produced 
naturally by Streptomyces nodosus and was first isolated in 1955 by Gold et al. It has 
been one of the most widely used antifungal drug worldwide, in the clinical practice due 
to its broad spectrum of action, fungicidal activity and low risk for the development of 
resistance. Previously, it was used as the first – line agent for invasive aspergillosis but 
nowadays, VRC has taken its place for the majority of the cases.  
The target of polyenes is the ergosterol, the most abundant sterol in the 
plasmatic membrane of fungi, involved in the maintenance of the fluidity, asymmetry 
and membrane integrity. The antifungal binds to the membrane ergosterol molecules 
forming aqueous pores in the membrane [161, 162]. These pores alter the permeability 
of the membrane, promoting the leakage of the citoplasmatic organelles, potassium 
ions, disrupting the membrane potential and consequently leading to cellular death 
[135; 162]. Amphotericin B also causes an oxidation-dependent stimulation of 
macrophages either due to autoxidation of the drug in conjunction with the formation of 
free radicals or due to an increase in the membrane permeability [163]. Amphotericin B 
presents poor oral absorption therefore all systemic preparations are IV formulations. 
Due to the similarity of ergosterol to the cholesterol of mammal cellular membranes, 
AMB B is even more toxic to the host than azole drugs. It is particularly nephrotoxic, 
impairing the renal function. It leads to a medical condition characterized by abnormal 
high levels of nitrogen-containing compounds in the blood, mostly related to a reduction 
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in the glomerular filtration of the blood in the kidneys, and loss of the ability to 
concentrate urine [161, 164]. At high levels AMB B can also inhibit the enzyme chitin 
synthase, involved in the synthesis of the cell wall [161]. The conventional AMB B 
deoxicolate formulation is more toxic to the host when compared to the more recently 
developed liposomal formulation. Amphotericin B is indicated for several different 
clinical situations: prophylaxis in patients with risk for serious fungal infections, empiric 
therapy in patients who have neutropenia and fever; treatment of candidiasis including 
candidal esophagitis and hepatosplenic candidiasis; severe candidiasis such as 
candidemia, endophthalmitis, and osteomyelitis; and for the treatment of aspergillosis, 
cryptococcosis, and the dimorphic mycoses [163]. It is also recommended for IC in 
neutropenic patients and for the treatment of infections due to Candida isolates either 
intrinsically resistant to azoles or after the development of resistance under azole 
therapy [165-166]. 
 
Figure 5 – Amphotericin B chemical structure. 
 
The Echinocandins 
 Echinocandins (figure 5) are the most recent class of antifungal agents 
available. The most used drugs in the clinical practice belonging to this class of 
antifungals are CSF (the first approved echinocandin), AND or MCF, which are 
molecules isolated from fungi and chemically modified. There is poor oral absorption of 
the echinocandins, and thus only IV formulations are available. Their target is the 1,3--
D-glucan synthase, encoded by the FKS gene, an enzyme necessary for synthesis of 1, 
3--D-glucan, one of the most important constituents of the fungi cell wall. The 1,3--D-
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glucan synthase is constituted by two subunits, Fksp and Rho1p. Fksp is the active site 
of the enzyme and is encoded by the genes FKS1, FKS2 and FKS3 [167, 168]. The cell 
wall plays a crucial role in the protection, morphology and rigidity of the cell, 
metabolism, ionic exchanges, antigen expression, primary interactions with the host and 
resistance to the immunological response of the host. The inhibition of the target 
enzyme leads to alterations in the cell wall structure, increased chitin content, reduction 
of the ergosterol and lanosterol content of the cellular membrane, ultimately leading to 
cellular lyses [135, 136, 161, 162]. Therefore, this class of antifungals is mostly 
considered fungicidal and demonstrates good in vitro and in vivo activity against a 
range of Candida species and is recommended as an alternative therapy for Aspergillus 
infections. However, against C. parapsilosis, C. guilliermondii and Aspergillus spp. 
these antifungals are only fungistatic [163, 168]. The echinocandins do not present 
major adverse side effects since the glucan target is not found in the mammalian cells. 
Echinocandins present no cross-resistance with other antifungal drugs [168, 169]. 
When clinical isolates present resistance to azoles, echinocandins are the first-line 
alternative antifungals to treat deep infections due to Candida spp., first CSF and more 
recently MCF and AND [170]. 
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Figure 6 – Echinocandins chemical structure. Each antifungal drug belonging to the class of the 
echinocandin presents a general chemical structure (A), differing in their side chains, namely, CSF, AND 
and MCF (B).  
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The Pyrimidine analogues 
 5- Flucytosine (figure 6), a fluorinated pyrimidine, analogue of cytosine, was one 
of the first antifungals available for the treatment of fungal infections from 1960. It is 
always used in combination with other antifungal agents such as AMB B, for example, 
for the treatment of cryptococcal meningitis. Its mechanism of action interferes with both 
the synthesis of nucleic acids and proteins. A cytosine permease enzyme drives the 5-
FC molecule inside the cell, where it is metabolized to 5 – flurouracil (5- FU). This 
product is later metabolized in 5 – fluorouridine triphosphate which substitutes the uracil 
in fungal RNA, altering pyrimidine metabolism and consequently protein synthesis. 5 - 
FU can also be converted in 5 – fluorodeoxyuridine monophosphate (5 – FUdRMP) a 
strong inhibitor of the enzyme thymidylate synthetase and thus interfering with fungal 
DNA synthesis [135, 162, 163, 171].  
 
 
Figure 7 – 5-Flucytosine chemical structure 
 
Other antifungal drugs belonging to different classes have been studied during 
the last years, namely, rapamycin, aureobasidin A or natural peptides derivatives such 
as hystatin among others [137].  
 First line antifungal treatment for candidemia and deep candidiasis remains 
controversial. It is usually recommended the use of echinocandins, FLC, or lipid 
formulation of AMB, but not AMB deoxycholate formulation due to its toxicity. Several 
factors are associated with the choice of the antifungal therapy namely, the clinical 
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status of the patient, the knowledge of the antifungal susceptibility profile of the infecting 
isolate, the drug toxicity and the patient’s prior exposure to antifungal agents [165].  
 Mortality rates of IC are still very high, despite the different classes of antifungals 
available with different mechanism of action, therefore alternative therapies are in 
development. The ideal antifungal should present a large spectrum of activity and 
should not be toxic to the host. To find this ideal antifungal, a specific target in the 
pathogen organism with no similar target in the host cells should be found, such as the 
unique fungi cell wall, and for example, presenting a low rate of development of 
resistance associated [162]. 
 
Antifungal Susceptibility Assays 
 Several different types of antifungal susceptibility assays have been developed 
throughout the years, reaching a turning point in the 1990s. Over the past 2 decades 
the determination of the susceptibility profiles changed from a nonstandardized 
procedure with no clinical importance, to a standardized technique, well controlled and 
of major importance to the physicians when dealing with fungal infections. Before the 
development of these standardized techniques, the determination of the MICs were 
inconsistent and could vary between laboratories up to 50000-fold [172]. The US 
Clinical Laboratory Standard Institute (CLSI), former National Committee for Clinical 
Laboratory Standards (NCCLS), first published in 1992 the standard macrobroth dilution 
protocol M27–P for susceptibility determination [173]. Reference methods for testing 
yeast and moulds have been developed and improved over the years due to the 
intensive research and global multi-laboratory collaborations. Different protocols were 
approved and breakpoints were established in order to interpret antifungal susceptibility 
assays. The latest versions of the different protocols developed are: the M27 – A3, 
including the supplemental protocol M27-S4 for macrobroth and microtiter yeast tests 
[174, 175], M38-A2 for microtiter mould testing [176], M44-A for yeast disk diffusion 
testing [177] and M51-P for mould disk diffusion testing [178]. To date, interpretive 
guidelines have only been established for 5-FC, some azoles such as FLC or VRC, and 
the currently available echinocandins such as AND, CSF and MCF.  
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 Although the reference techniques are extensively used worldwide with validated 
results, they present some flaws, such as the lack of reliable detection of resistance to 
AMB B, the poor growth of non- fermentative yeasts such as Cryptococcus neoformans, 
lack of reproducibility when testing echinocandins and the need for physicians to 
establish breakpoints to interpret the susceptibility results of the filamentous fungi [179, 
180]. Another problem is the implementation of these standard reference procedures in 
the clinical laboratories since they recommend complex methods that are time and labor 
intensive. Therefore, the CLSI committee has approved an agar diffusion technique for 
yeast testing, the protocol M44-A [177], in 2004. Voriconazole and FLC disks were 
already approved to test the susceptibility in vitro of Candida species and echinocandin 
disks are under study for standardization. Techniques such as Etest (AB Biodisk), 
Sensititre YeastOne (Trek Diagnostic Systems Ltd), Neo-Sensitabs (A/S Rosco), 
Fungitest (Bio-Rad), Vitek (bioMerieux) and others can be used to detect the 
resistance in vitro to FLC and other azoles in Candida isolates. These tests are a good 
alternative to the microdilution protocol, since the discrepancies obtained when 
compared with the reference MIC values of azole agents are less than 5% [181, 182]. 
Additionally, some of these tests have also presented very reliable results in the 
detection of resistance to echinocandins and Etest has proven to be the most reliable 
method to detect isolates with high MIC values to AMB B.  
 While new protocols were being revised and improved by the CLSI committee, 
the European community involved in the antifungal susceptibility research field also 
began to work on a standard method. The European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) developed reference protocols in order to determine 
the susceptibility profiles of Candida species and filamentous fungi [183-186]. The aim 
of the EUCAST is to standardize the antimicrobial breakpoints and the susceptibility 
testing in Europe in order to establish reproducible methods, comparable results and 
interpretation. It distinguishes between clinical breakpoints and epidemiological cut – off 
values. Clinical breakpoints define the organism as susceptible, intermediate, and 
resistant to antifungal drugs. Susceptible and resistant categories are related to a 
higher probability of clinical success or clinical failure, respectively. The clinical outcome 
associated with an intermediate category is uncertain. Clinical breakpoints should be 
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used every day in the clinical laboratories to advise the physician concerning the 
therapy to be applied. Epidemiological cut off values are based on the wild-type MIC 
distribution of each microorganism and are used as the most sensitive measure of 
development of resistance in the hospitals and in the community. Additionally, they are 
quite important in the implementation of strategies to stop the development of 
resistance.  
 Recently, breakpoints for some antifungal compounds have been set in the 
EUCAST protocols. Although the CLSI and EUCAST reference methodologies are 
different, the results obtained are equivalent [187, 188]. As more drugs reach the 
market, the CLSI and EUCAST committees will be challenged to expand the existing 
documents, especially when new classes of drugs are introduced.   
 
 One of the major concerns for microbiologists is the poor relationship between in 
vitro susceptibility profiles and the response of clinical isolates to antifungal treatments. 
Several factors may be associated to these differences namely pharmacogenomic, 
pharmacokinetics and interactions with other drugs/concomitant therapies [189]. On the 
other hand, when resistance is detected in vitro most certainly the clinical isolates 
present a resistant phenotype in vivo, escaping the antifungal action of the drugs due to 
the presence of resistance mechanisms.  
 
Antifungal Resistance Mechanism  
 Fungal pathogens can suffer positive selection due to the presence of antifungal 
drugs such as the development of antifungal resistance. Different mechanisms of 
resistance to different classes of antifungals have been described for Candida spp.: 
mutation or overexpression of ERG11 gene encoding for the drug target enzyme 
lanosterol 14α – demethylase- Erg11p, mutations in genes encoding for other enzymes 
of the ergosterol biosynthesis pathway, such as ERG3 gene, compensating for the 
accumulation of the toxic ergosterol intermediates in the cells, overexpression of efflux 
pumps belonging to the ATP Binding Cassette (ABC) and Major Facilitator Superfamily 
(MFS) of transporter proteins, mutations in the FKS1/ 2 genes or even the presence of 
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complex multicellular structures such as biofilms   [137, 190]. Some resistant 
phenotypes to echinocandins have been described in C. albicans, C. glabrata, C. 
parapsilosis and C. krusei, isolated from patients under a long period of echinocandins 
therapy [191-194]. Also, resistance to 5 –FC develops very rapidly in most fungi 
especially if used alone. Most of these resistant isolates present mutations in the 
cytosine permease, cytosine deaminase or FUR1 gene (C301T) [137, 195]. The 
enzymes and genes are crucial for the entrance of the drug into the cell and to the 
conversion of 5 – FC into 5 –fluorouracil acid. On the other hand, some pathogens 
present intrinsic resistance to some antifungals due to specific traits in their genomes, 
such as C. krusei intrinsic resistance to FLC.   
 
Ergosterol biosynthesis pathway: an unsuitable antifungal target for C. krusei 
 The ergosterol biosynthesis pathway converts acetyl-CoA into ergosterol, similar 
to what happens in the cholesterol biosynthetic pathway in mammals. The enzyme 
Erg11p is one of the most important enzymes of the biosynthetic pathway, and is one of 
the main targets of the azole drugs. When the azoles bind to this enzyme, inhibiting its 
activity, toxic precursors 14-methylated accumulate in the yeast cells. Several 
resistance mechanisms associated to the ergosterol biosynthesis pathway, have been 
described in different strains of Candida spp.: mutations in ERG11 gene sequence [196] 
and ERG11 gene overexpression [197], mutations in the ERG2 gene and ERG3 gene 
encoding for the enzymes sterol D8, 7 - isomerase and 5, 6 –desaturase, respectively 
[161, 198]. The enzyme 5, 6 –desaturase is involved in the final stage of ergosterol 
biosynthesis and converts non-toxic 14-methylated intermediates which accumulate due 
to the azoles inhibitory effect in the toxic sterol 14-metilergosta–8, 24(28)-dien-3, 6-diol. 
Organisms deficient in this enzyme produce 14- methylfecosterol and remain viable 
when 14α – demethylase activity is inhibited [161, 199]. All these alterations in gene 
sequence lead to a protein with an altered structure, reducing the affinity of the azoles 
to the binding site of the enzyme, therefore not exerting its antifungal effect.  
 Candida krusei is a peculiar case since its intrinsic resistance to FLC is 
associated to a diminished affinity of the drug to the target enzyme Erg11p, but not due 
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to mutations or polymorphisms conversely to what is described for other Candida sp. 
[196].  Radioactivity studies have shown a reduced inhibitory effect of FLC in the 
synthesis of ergosterol, when compared to ITC or KTC [200]. Additionally, it was also 
demonstrated through interaction studies, between different azoles and the cytochrome 
P450 enzyme, a lower affinity of FLC to the binding site of the enzyme, followed by KTC 
and with ITC presenting the highest affinity, therefore explaining in part the intrinsic 
resistance to FLC of C. krusei strains [200]. Comparative studies between C. krusei and 
C. albicans suggest that there are qualitative differences in the Erg11p in the two 
different species of Candida.  It was described that the concentration of FLC required to 
inhibit the synthesis of ergosterol by 50% was 16 to 46-fold higher in cell extracts of C. 
krusei than in cell extracts of C. albicans [201].  
Efflux mediated by ABC transporters 
 There are two types of multidrug transporter families, the ABC transporters 
encoded by CDR genes (Candida Drug Resistance), which use adenosine triphosphate 
(ATP) as energy source and the MFS transporters, such as MDR1 gene (multidrug 
resistance), which uses a proton gradient across the membrane as the driving force for 
transport [202]. 
 ABC proteins are composed by two trans – membrane domains (TMDs) and two 
cytoplasmic nucleotide binding domains (NBDs). The NBDs of all ABC transporters 
have in common the amino acid sequence identity and typical motifs, regardless the 
origin and nature of the substrate transported. Studies indicate that the TMDs are 
associated to the formation of substrate binding sites; however this is not enough for the 
transport of substrates across the phospholipids bilayer of the membrane [203, 204]. 
The transport requires energy from the hydrolysis of ATP carried out at the NBDs 
located at the periphery of the cytoplasm. The substrate specificity of ABC transporters 
is quite variable due to the high divergence of primary sequences. The most frequent 
mechanism of resistance to azole drugs in Candida spp. and in filamentous fungi are 
associated to efflux pumps, i. e., the alteration of the drug transport due to 
overexpression of efflux pumps encoded by CDRs genes or the increase of the efflux 
pumps activity [205-208].  
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 The MFS transporter proteins are involved in the symport, antiport, or uniport of 
various substrates. MFS transporters obtain the necessary energy for the transport of 
substrates from an electro-chemical proton-motive force, composed by an electrical 
potential () and a chemical proton gradient (pH = pHexternal - pHinternal). In yeasts, the 
MFS-MDR transporters promote a proton antiport and are divided in two groups: the 
drug: H+ antiporter-1 (12 TMS) DHA1 family, and the drug: H+ antiporter-2 (14 TMS) 
DHA2 family [209, 210]. MDR1 (formerly BENr for benomyl resistance) and FLU1 
(fluconazole resistance) genes were identified in C. albicans as belonging to MFS 
transporter family and to be related to resistance.  
 
 ABC1 and ABC2 genes were the first genes described in C. krusei encoding for 
the efflux pumps, Abc1p and Abc2p, and to be associated to azole resistance [211]. 
These genes were expressed at low constitutive levels in log phase cultures but 
upregulated in the stationary phase. It was suggested that FLC and other azoles are 
substrates for the transporter protein Abc1p therefore FLC resistance could be 
associated not only to the low affinity of the antifungal to the enzyme Erg11p but also to 
efflux activity [211]. In a previous study by Venkateswarlu K, et al, it was already 
demonstrated that resistance to different azoles other than FLC such as ITC could be 
associated to transporter proteins promoting drug efflux [200]. More recently, ABC1 
gene from C. krusei was expressed in S. cerevisiae and it conferred resistance to azole 
drugs [16].  
 The MFS transporter proteins are not described to be associated to resistance to 
azoles in C. krusei conversely to other Candida species such as C. albicans [209]. J 
Guinea et al, evaluated the effect of carbonyl cyanide 3-chloro-phenylhydrazone 
(CCCP), in the MIC values of different antifungals in C. krusei clinical isolates. CCCP is 
a protonophore which collapses the transmembrane pH [213, 214] and hence inhibits 
the enzymes belonging to the MFS transporter family. No significant difference was 
registered in the MIC values in the presence/absence of the protonophore therefore 
they concluded that this family of proteins was not involved in C. krusei azole resistance.  
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Acquisition of mutations to echinocandins 
 Two different mechanisms have been associated to echinocandin resistance in 
Candida spp.: mutations in the “hot – spot” regions (HS1 and HS2) of FKS1 and FKS2 
genes encoding for the major and presumed catalytic subunit of 1, 3 – ß – D- glucan 
synthase and a compensatory increase in the production of chitin, the second structural 
cell wall polysaccharide [215]. Point mutations associated to echinocandins resistance 
have been described in different species of Candida namely, C. albicans, C. glabrata, C. 
krusei, C. tropicalis [193, 216-219]. Specifically, the acquisition of resistance to 
echinocandins has been described in three clinical cases involving C. krusei infection 
[194, 220, 221]. However, in only two of the cases was described an alteration in the 
FKS1 gene in the hot spot region (T2080K, resulting in a Phe655 – Cys substitution) 
after antifungal therapy [194, 221]. In the other clinical case involving an acute 
myelogenous leukemia patient, administered CSF during 17 days, 50 mg/day, no 
mutation in FKS genes was described, therefore other resistance mechanism would be 
associated [220]. There is also some evidence that resistance may be due to efflux 
pumps activity in the fungal cell wall and over expression of cell wall transporter 
proteins [222]. 
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Abstract 
 
 Candida krusei has been documented as an emerging pathogen causing 
nosocomial outbreaks. The consecutive isolation of C. krusei strains in three patients 
admitted to the same hospital department within 2 months lead us to consider the 
possibility of an outbreak. Additionally, C. krusei isolates were collected from the room 
surfaces, whereas another isolate had been recovered from the blood of one patient 2 
years before. HinfI DNA restriction endonuclease-based analysis of all C. krusei isolates 
was performed and restriction profiles were compared. Surprisingly, isolates from 
different patients were unrelated, whereas isolates from biological products of the same 
patient showed indistinguishable HinfI restriction patterns and were similar to those 
obtained from the surrounding environment of the respective patients. The study 
approach revealed the endogenous origin of the C. krusei infectious episodes observed 
and demonstrated that, subsequent to colonizing a patient, C. krusei can be involved in 
infectious episodes distant in time. The hypothesis of an outbreak was excluded, 
although we believe that the methodology employed in the present study represents a 
valuable tool for diagnostic and epidemiological surveys. 
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Background 
 
In the last two decades, invasive fungal infections in hospitalized patients have 
increased significantly worldwide. According to data obtained from USA and Europe, 
Candida species represent, respectively, the fourth and sixth most frequent cause of 
invasive healthcare-related infections [223, 224], accounting for 8-15% of all episodes 
of sepsis episodes acquired in hospital settings [35]. Inherent to these types of infection 
are the extremely high morbidity and mortality rates, particularly among 
immunocompromised patients [24, 36]. 
Fluconazole is one of the antifungal agents mostly used in both prophylactic and 
therapeutic protocols. Fluconazole prophylaxis has been associated with a decrease in 
the prevalence of Candida species such as C. tropicalis and C. albicans, and to an 
increase in that of C. krusei and C. glabrata [35]. C. krusei presents intrinsic resistance 
to FLC and, to some extent, reduced susceptibility to AMB B [225]. 
Infectious outbreaks in hospitals, especially in ICU, represent a serious health 
problem and are mainly due to C. lusitaniae, C. albicans, C. parapsilosis, and C. krusei 
[226-230]. Many factors may account for their occurrence (e.g. barrier loss, lack of 
proper infection control measures by health care workers when managing patients, 
resistance to prescribed antifungal drugs as well as insufficient drug levels.  
Molecular methods represent a powerful tool to clarify transmission pathways in 
health care facilities, (i.e. to investigate the occurrence of possible outbreaks). 
Techniques such as karyotyping, restriction fragment length polymorphism (RFLP) 
analysis by PFGE, southern blot hybridization, PCR fingerprinting and RAPD 
fingerprinting have been extensively used for Candida typing [98, 231-234]. Restriction 
endonuclease analysis has been described in the last decade as a valuable tool for 
Candida spp. characterization. Restriction endonuclease analysis of the mtDNA was 
first applied in biotechnology industry in order to characterize yeast strains used for 
wine fermentation [109, 110] and, more recently, to discriminate between Candida 
clinical strains [111 -114]. The data obtained demonstrate the relevance of using 
molecular genetic methods in many different areas, including taxonomic, ecological and 
clinical surveys. 
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Recently, we were challenged by a hypothetical outbreak as a result of C. krusei 
in the neutropenia unit of the Hematology Department of Hospital S. João, Porto, 
Portugal. Within a short period of time, several C. krusei isolates were cultured from 
biological products of three patients. In addition, C. krusei was found in the surrounding 
environment of the patients. All isolates were compared using mtDNA REA, which is a 
convenient and powerful tool that allows valid comparisons between isolates of the 
same yeast species.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Candida krusei reservoir in a neutropenic unit: molecular evidence of a foe? 
 
- 50 - 
Patients and Methods 
 
Patients 
Patient A was a 41-year-old male with acute lymphoblastic leukemia (T/NK) 
diagnosed in July 2006. In August 2008, the patient was initially treated with amoxicillin 
and ciprofloxacin because of undetermined fever. When symptoms remained 
unchanged, a myelogram was performed; a first relapse of the hematological disease 
was diagnosed. He was admitted to the Neutropenia Unit for salvage intensive 
chemotherapy with fludarabine, idarubicin and ara-C, followed by growth factor (G-
CSF), administered through a central venous catheter. Upon the onset of the aplastic 
period (28 August) he received antimicrobial treatment for 2 weeks (ciprofloxacin, 
amoxicillin-clavulanic acid, imipenem, acyclovir and FLC 200 mg/day). At the time of 
fungemia detection he displayed the following hematologic parameters: white blood 
cells 0.03x109cell/L, hemoglobin level 8.5 g/dl and blood platelets levels 11x109cells/L. 
As soon as C. krusei was identified, the patient was started on CSF for 12 days without 
improvement; the treatment was then changed to AMB B. This patient had previously 
developed a fungemia episode as a result of C. krusei during chemotherapy in 2006 
and a corresponding isolate had been stored at -70ºC. The patient remained in room 
number 1 from August to October 2008. 
Patient B was a 53-year-old mal with non-Hodgkin´s lymphoma, who was 
admitted to room number 2 for 3 weeks in September 2008. He was administered 
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) followed by G-
CSF. On September 12 2008, he was started on CSF but as a result of sustained fever 
on day 5, treatment was changed to VRC, completing 14 days of antifungal therapy. He 
never received FLC. At that fungemia episode he displayed the following hematologic 
parameters: white blood cells 2.41x109cell/L, hemoglobin level 9.3 g/dl and blood 
platelets levels 73x109cells/L.  
Patient C was a 60-year-old male with acute myeloid leukemia, secondary to 
myelodisplastic syndrome; he was admitted to room number 2 for 3 weeks in October 
2008, subsequent to patient B. He received Ara-C, Etoposide and doxorubicin for 5 
days, followed by another 5 days of Ara-C; he was also prescribed amoxicillin, 
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ciprofloxacin and allopurinol. In addition, prophylaxic treatment included imipenem, 
vancomycin, FLC and acyclovir from 29 September to 20 October 2008. On that latest 
date he displayed the following hematologic parameters: white blood cells 0.6x109cell/L, 
hemoglobin level 9.8 g/dl and blood platelets levels 24x109cells/L.  
Patient D served as a typing control; one single C. krusei strain was recovered 
from the patient´s bronchial secretions in September 2008 upon his admission to the 
Internal Medicine Department. 
 
Clinical strains 
Eighteen C. krusei isolates were collected from different clinical specimens 
(blood, urine, stools, and bronchial secretions) of the above mentioned patients 
admitted to the neutropenia unit within a 2-month period. Additionally, a previous C. 
krusei isolate (2006) from a blood culture of patient A was included in the study, as well 
as a C. krusei isolate obtained from the control patient D. All isolates were identified 
using the automatic system Vitek2 YBC identification cards (BioMérieux, Paris, France), 
stored at -70ºC in Brain Heart infusion (Merck KGaA, Darmstadt, Germany) with 10% 
glycerol and sub-cultured twice in Sabouraud agar (Merck KGaA) to ensure purity prior 
to experimental assays. 
 
Environmental strains 
 Several environmental samples were collected from the patients’ rooms (1 and 
2) using Sabouraud agar contact plates (Merck KGaA, Germany); two C. krusei isolates 
were cultured: one from the bedside table of patient A (room 1) and another from the 
bed of patient C (room 2). The isolates were characterized and stored as described 
above for clinical samples. Air samples were collected by filtration with a MAS-100 Eco 
instrument (Merck Eurolab, Switzerland), containing Sabouraud agar plates (Merck 
KGaA); no C. krusei isolates were obtained.  
 
Antifungal Susceptibility Testing 
 Voriconazole (Pfizer), PSC (Schering- Plough; New Jersey, USA), AMB B 
(Bristol Meyers Squibb, NY, USA), CSF (Merck, Rahway, NJ, USA) and AND (Pfizer) 
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stock solutions were prepared according to CLSI protocols M27-A3 [174], and 
maintained in stock solution at -70°C until use. Minimal inhibitory concentration of each 
antifungal drug was determined according to CLSI protocol [174].  
 
Total genomic DNA extraction 
 Yeast cells were cultured overnight at 30ºC in 10 ml of YPD liquid medium, with 
continuous orbital shaking at 180 rpm, and subsequently collected by centrifugation. 
Total DNA was extracted using Phenol:Chloroform:Isoamyl alcohol 25:24:1, precipitated 
using 100% ice-cold ethanol and redissolved in 200 l of Tris-EDTA (TE) buffer. The 
DNA was treated with 20 g of RNase (Applichem, Darmstadt, Germany), incubated at 
37ºC for 30min to 1h. For final precipitation, 20 l of 4 M Ammonium acetate pH 4.8 
(Sigma –Aldrich, Germany) and 600 l of ice-cold 100% ethanol (Applichem) were 
added and samples were incubated overnight at -20ºC. The DNA was re-dissolved in 
TE buffer 1x, assessed in a biophotometer 6131 (Eppendorf®, Hamburg, Germany) and 
adjusted to a final concentration of 2.0-2.5 g/l. To assay DNA integrity, about 3-5 g 
of DNA was run in  agarose gel (1%w/v) (Sigma –Aldrich) in Tris- Borate-EDTA (TBE) 
buffer 1x and stained with ethidium bromide 0.5 mg/ml. DNA samples were stored at -
20ºC for subsequent use. 
 
Restriction Endonuclease Analysis (REA) 
 For each sample, a reaction mixture was prepared containing 1x Hinf I enzyme 
reaction buffer (Metabion, Germany), 1g/l RNase, 0.5U/l Hinf I restriction enzyme 
(Metabion), approximately 25 to 30 g of total DNA and DNAse-RNAse free water up to 
20 l final volume; reaction tubes were incubated overnight at 37ºC. Restriction was 
ended upon HinfI inactivation by incubating 20 min at 80ºC. The total reaction mixture 
was run on a 1% agarose gel (20cmx24cm), 120mv, for 3-5h, stained with ethidium 
bromide solution (0.5mg/ml) and the DNA visualized under UV light.  
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Results analysis 
 Restriction patterns were analyzed using the UVIDOC 12.6 software for 
Windows (Topac Inc., Cohasset, MA, USA) and the resulting groups of strains were 
compared. 
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Results and Discussion  
 
There have been an increased number of reports describing non-albicans 
Candida hospital outbreaks. Given that C. krusei is not the main pathogen causing 
nosocomial infections, the detection of simultaneous episodes at the neutropenia unit of 
our hospital lead us to consider the possibility of an outbreak. The C. krusei isolates 
were all susceptible to all the antifungals assayed (FLC was not tested since C. krusei 
presents intrinsic resistance to this agent). Variations in the antifungal MICs for different 
isolates were not significant. The MICs of amphotericin B were from 0.06 to 1µg/ml, for 
CSF from 0.125 to 1µg/ml, for AND 0.06µg/ml; for VRC from 0.25 to 2µg/ml and for 
PSC from 0.03 to 0.5µg/ml.   
The routine biochemical identification protocols or antifungal susceptibility 
profiles are usually not sufficient to either corroborate or exclude an outbreak 
hypothesis. REA for Candida species was first described by Scherer and Stevens 
(1987) who considered this method to be an extremely valuable tool for epidemiological 
studies [235]. Fujita et al (2000) described HinfI restriction patterns exhibiting a superior 
discriminatory power among distinct Candida isolates compared to patterns with other 
enzymes such as EcoRI or MspI [113]. Additionally, Sancak et al (2004) established a 
correspondence of almost 100% between the results obtained with HinfI REA and PCR 
methodologies [114]. In the present study, a total of 22 C. krusei isolates (20 clinical, 
two environmental) were analyzed using REA. A high number of C. krusei isolates was 
obtained from different biological products of patient A in distinct periods of time. All of 
them showed the same restriction pattern, including the isolate recovered in 2006 from 
a blood culture (ABC1) (figure 1, lanes ABC1, ABC2 and ACVC), indicating that they are the 
same strain. 
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                             M ABC1 ABC2           M ACVC11 AE9                    DBS BBS CS  M         CE 
 
Figure 1 – Restriction Endonuclease patterns of Hinf I-digested DNA obtained after agarose gel 
electrophoresis. Each pattern corresponds to C. krusei isolates from patients A, B, C and D (upper case 
letters), from different biological products (BC – Blood cultures; CVC- central venous catheter; BS - 
bronchial secretions; S – stools), and to C. krusei isolates from the room environment of patients A and C 
(AE and CE, respectively); M- Molecular Weight Marker (1-kb DNA ladder, Metabion). 
 
Most certainly, this patient harbors a reservoir of C. krusei and was colonized 
throughout a long period of time, as described for Acinetobacter [236] and 
Pseudomonas [237].  This is the first report, to our knowledge, describing a long-lasting 
colonization by C. krusei. These results have implications in terms of prophylactic 
measures (i. e. FLC is not recommended in a patient with previous isolation of C. 
krusei). Other antifungals such VRC or AMB B are more likely to be efficient in these 
cases [238, 239]. 
The C. krusei isolates from each patient yielded distinct Hinf I restriction patterns 
suggesting that the isolates were different strains (figure 1, lanes ABC2, BBS, CS), at the 
same time discarding the hypothesis of an outbreak in the neutropenia unit where the 
patients were admitted. The C. krusei strain isolated from patient D showed a pattern 
distinct from those isolated from the remaining patients (figure 1, lane DBS), as 
expected. 
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 The two environmental C. krusei isolates collected from the surfaces of the 
rooms where patient A (AE) (room 1) and patients B and C (CE) (room 2) had stayed 
were different, as depicted in figure 1. This excludes the possibility of different C. krusei 
strains being transmitted as a result of patient handling by health care workers. 
However, both the environmental and the clinical C. krusei isolates associated with the 
same patient displayed an undistinguishable restriction pattern, as shown in figure 1 
(lanes ACVC and AE vs. CS and CE), suggesting a putative environmental reservoir and 
the possibility of subsequent transmission from it to other patients. Our results 
emphasize the need to enhance preventive infection control measures, both when 
handling the patients directly and when cleaning patients´ facilities particularly those 
admitting neutropenic patients. Indeed, a study by Berrouane et al. described the 
relatedness among C. krusei clinical isolates obtained from different biological products 
from patients and health care workers [126].  
 As described in the present study, we were able to exclude the hypothesis of an 
outbreak occurring in the neutropenia unit throughout the time period considered, 
supporting the usefulness and suitability of the REA methodology. Moreover, the 
present study provided very useful information concerning C. krusei reservoirs existing 
in patients and their surrounding environment.  
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“Acredite que você pode, assim você já está no meio do caminho” 
Teodore Roosevelt; 26º Presidente dos Estados Unidos da América, 
historiador, naturalista, explorador, escritor, militar. 1858-1919. 
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Abstract  
 
Candida krusei is an important agent of opportunistic infections that often 
displays resistance to several antifungals. We describe here the in vivo acquisition of 
resistance to voriconazole by C. krusei isolates recovered from a leukemia patient 
under a long period of VRC therapy. In order to mimic the in vivo development of 
voriconazole resistance, a susceptible C. krusei isolate was exposed daily to 1g/ml of 
voriconazole in vitro. Interestingly, after 5 days of exposure to voriconazole, a MIC of 4 
g/ml was achieved; this value remaining constant after 25 additional days of treatment 
with VRC, and also after 30 consecutive days of incubation in voriconazole -free 
medium. Our objective was to determine the associated molecular resistance 
mechanisms, such as expression of efflux pumps genes and ERG11 gene mutations, 
among the resistant strains.  
Synergistic effects between the efflux blocker Tacrolimus (FK506) and 
voriconazole were found in all the resistant strains. Moreover, ABC1 gene expression 
increased over time in both the in vivo- and in vitro - induced resistant strains, in 
contrast to the ABC2 and ERG11 genes, whose expression was invariably lower and 
constant. ERG11 gene sequencing showed two different types of mutations, i.e., 
heterozygosity at T1389T/C, corresponding to a synonymous mutation, in C. krusei 
strains and a missense mutation, at position T418C, resulting in a change from Tyr to 
His, among resistant C. krusei clinical isolates. This study highlights the relevance of 
ATP-dependent efflux pump (namely, Abc1p) activity in voriconazole antifungal 
resistance and describes new mutations in the ERG11 gene among resistant C. krusei 
clinical isolates.  
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Background 
 
In recent years, we witnessed the emergence of low-pathogenicity non-albicans 
Candida species, such as C. krusei. It is an opportunistic pathogen especially among 
patients with hematologic malignancies and those undergoing bone marrow 
transplantation [56, 240]. Mortality rates among such patients with C. krusei fungemia 
are unacceptably high, ranging from 60 to 80% [56]. Nevertheless, few studies 
concerning the epidemiology and antifungal susceptibility profile of C. krusei are 
available. C. krusei ranked in fifth place among 22 different species of Candida, 
accounting for 3.3% of all Candida isolates both in Europe and North America [84, 130]. 
Candida krusei is often described as a multidrug-resistant (MDR) fungal 
pathogen due to its intrinsic resistance to FLC and decreased susceptibility to 5-FC, 
AMB B and KTC [127, 128]. Resistance to FLC is a major problem among neutropenic 
and critically ill patients since this drug is frequently used for prophylaxis [241]. Candida 
krusei resistance to echinocandins was also described among patients with acute 
myelogenous leukemia [220, 221]. 
Two major mechanisms of resistance to azoles are observed in C. krusei, i. e., 
reduced intracellular drug accumulation due to the activity of efflux pump proteins 
Abc1p and Abc2p and alterations in the target enzyme, cytochrome P450 lanosterol 
14-demethylase, encoded by Erg11p, which is involved in the ergosterol biosynthesis 
pathway [201, 211]. Such efflux pumps belong to the ATP Binding Cassette (ABC) 
transporter family of proteins encoded by ABC1 and ABC2 genes. Venkateswarlu et al 
described a group of clinical isolates of C. krusei resistant to ITC due to activity of efflux 
pumps [242]. However, the scarce information available regarding efflux pump activity 
and gene expression following azole exposure makes C. krusei resistance to azoles 
poorly understood [16]. On the other hand, it is not yet possible to explain the reduced 
affinity of azoles, namely FLC, for the target, the Erg11 protein binding site [201]. No 
resistance-conferring alterations in the ERG11 gene sequence have yet been described 
for C. krusei, in comparinson with findings for C. albicans [196].  
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We addressed the molecular mechanisms of resistance acquired in vivo, i.e. in 
voriconazole (VRC)- resistant C. krusei strains isolated from a leukemia patient 
undergoing VRC therapy, or following induction in vitro, i.e., in VRC-resistant C. krusei 
strains repeatedly incubated with VRC at sub-inhibitory concentrations. We concluded 
that repeated exposure to VRC results in the development of concomitant resistance 
mechanisms, namely, enhanced activity of efflux pumps encoded by the ABC1 gene 
and single-point mutations in ERG11 gene.  
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Material and Methods 
 
Patient clinical data  
A 41-year-old male patient, admitted to Centro Hospitalar S. João (Porto, 
Portugal), was diagnosed with acute lymphoblastic leukaemia (T/natural killer [NK] 
cells) in August 2008. Due to protracted fever that persisted after antibacterial 
treatment, a myelogram was performed and a first relapse of the hematological disease 
was diagnosed. The patient was admitted at once at the Neutropenic Unit for salvage 
chemotherapy with fludarabine, idarubicin and 1-ß-D-arabinofuranosyl cytosine  (Ara-
C), followed by the growth factor granulocyte colony-stimulating factor (G-CSF), 
administered through a central venous catheter (CVC). Due to the persistent fever, the 
patient began treatment with 200 mg/daily of FLC. Candida krusei was first isolated 
from a blood culture after 9 days of FLC therapy; a second blood culture was positive 
for C. krusei at day 14. Fluconazole treatment was suspended and the patient began 
treatment with VRC at 200mg/day. During the initial 24 days of VRC therapy, several C. 
krusei isolates were recovered from blood cultures and from other biological samples; 
subsequently, C. krusei was recovered only from bronchial secretions and stools 
samples (figure 1). The patient had undergone VRC therapy for 216 days upon his 
death in April 2009.   
All of the clinical isolates were identified using Vitek 2 YBC identification cards 
(bioMérieux, Marcy l’Etoile, France) and were stored at -70ºC in brain heart broth 
(Merck KGaA, Darmstadt, Germany) with 40% glycerol. Prior to experiments, isolates 
were subcultured twice in Sabouraud agar (Merck KGaA, Darmstadt, Germany) to 
ensure the purity of cultures.  
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Figure 1 - Induction of resistance to voriconazole in vivo. The timeline of antifungal therapy and the 
recovery of C. krusei clinical strains from the leukemia patient, with the respective susceptibility profiles and 
relative gene expression levels is shown. ID, identification; S, susceptible; R, resistant.  Patient death. *P 
< 0.05   
 
Antifungal Drugs and Susceptibility Testing 
 Stock solutions of VRC (Pfizer, Groton, USA), PSC (Schering- Plough; New 
Jersey, USA), FLC (Pfizer, Groton, USA), AMB B (Bristol Meyers Squibb, New York, 
USA), CSF (Merck, Rahway, USA), AND (Pfizer, Groton, USA) and MCF (Astellas 
Pharma Inc., Tokyo, Japan) were prepared according to the M27-A3 and M27-S4 
protocols of the Clinical and Laboratory Standards Institute (CLSI) and were maintained 
at -70°C until use [174, 175]. Minimal inhibitory concentrations were determined for all 
C. krusei isolates according to the same protocols. The VRC susceptibility profiles of 
the C. krusei isolates were determined in accordance with MICs of <0.5 µg/ml 
(susceptible), 1.0 µg/ml (susceptible dose dependent) and > 2.0 µg/ml (resistant). 
Visual readings were performed after 24h and 48h of incubation, according to the same 
protocols. C. krusei type strain ATCC 6258 from the American Type Culture Collection 
was used as a control, as recommended [174, 175]. 
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Molecular typing  
All of the clinical isolates recovered from the leukemia patient were evaluated for 
their genetic relatedness, in order to determine whether the patient was colonized by 
the same C. krusei strain. 
Total genomic DNA extraction. C. krusei isolates were cultured overnight in 10 
ml of yeast extract-peptone-dextrose (YPD) liquid medium at 35ºC, at 150 rpm, and 
subsequently collected by centrifugation at 1610xg for 10min at room temperature 
(Universal 320 R, Hettich). Total DNA was extracted using phenol/chloroform/isoamyl 
alcohol (25:24:1; Sigma-Aldrich, Munich, Germany), precipitated with 100% ice-cold 
ethanol (Applichem, Darmstadt, Germany), and redissolved in 200 µl of TE buffer. The 
DNA was treated with 20 µg of RNase (Applichem, Darmstadt, Germany) and incubated 
at 37ºC for 1 h. For final precipitation, 20 µl of 4 M ammonium acetate (pH 4.8) (Sigma-
Aldrich, Munich, Germany) and 600 µl of ice-cold 100% ethanol (Applichem, Darmstadt, 
Germany) were added and samples were incubated overnight at – 20ºC.  
DNA samples were resuspended in 1x TE buffer, the concentration was 
adjusted to 2.0-2.5 g/l and samples were stored at -20ºC for later use.  
 
Restriction Endonuclease Analysis (REA). For each sample, a reaction mixture 
containing: 1x HinfI enzyme reaction buffer (Metabion, Martinsried, Germany) 1g/l 
RNase (Applichem, Darmstadt, Germany), 0.5 U/l HinfI restriction enzyme (Metabion, 
Martinsried, Germany), approximately 25 to 30 g of total DNA and DNAse/RNAse-free 
water up to a final volume of 20 l was prepared as described by Ricardo et al [243]; 
reaction tubes were incubated overnight at 37ºC. Total reaction mixture was run on a 
1% agarose gel (20cm by 24cm, 120 mv) for 3 to 5 h, stained with ethidium bromide 
solution (0.5mg/ml; Applichem, Darmstadt, Germany) and visualized with UV with a 
Chemidoc XRS+ imaging system (Bio-Rad, Hercules, USA). Restriction patterns were 
analyzed using the Image Lab Software (version 4.0.1; Bio-Rad, Hercules, USA) and 
the different isolates were compared for restriction pattern similarities. A nonrelated C. 
krusei isolate recovered from stools from a different patient was used as a control. 
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Random Amplification Polymorphic DNA. Random amplification polymorphic 
DNA (RAPD) analysis was performed as described previously [244], with some 
alterations. Briefly, the reaction mixture for RAPD analysis contained 1x Dream Taq 
enzyme reaction buffer, 0.04 U/l DreamTaq DNA Polymerase, 0.2 mM 
deoxynucleoside triphosphates (dNTPs), 2 mM MgCl2 (all from Fermentas, Vilnius, 
Lithuania), 0.4 M Primers OPA-18 (5’ – AGCTGACCGT- 3’) or OPE-18 (5’ -
GGACTGCAGA- 3’) (STABVida, Lisbon, Portugal), 200 ng total DNA and 
DNase/RNase-free water up to a final volume of 25 l. All PCRs were performed in an 
Eppendorf RealPlex2 Mastercycler (Eppendorf, Hamburg, Germany) and the reaction 
parameters were one cycle of 95ºC for 2min; 38 cycles of 95ºC for 1 min, 36ºC for 1 min 
and 72ºC for 2 min; and one cycle of 72ºC for 10 min. The amplified DNA fragments 
were analyzed by electrophoresis in a 2% agarose gel at 120 mv, for 2 h. The agarose 
gel was stained with ethidium bromide solution (0.5 mg/ml; Applichem, Darmstadt, 
Germany) and visualized with UV light with the Chemidoc XRS+ imaging system. 
Electrophoresis patterns were analyzed using the Image Lab Software (version 4.0.1).  
 
In vitro induction of resistance  
 A VRC-susceptible C. krusei isolate, recovered from the leukemia patient before 
VRC antifungal therapy, was repeatedly incubated with VRC. Briefly, a single, randomly 
selected colony from a fresh 24-h culture on Sabouraud agar was suspended in 10 ml 
of RPMI 1640 medium buffered to pH 7.0 with 0.165M MOPS 
(morpholinepropanesulfonic acid) (both from Sigma-Aldrich, Munich, Germany), in the 
presence of VRC at 1 µg/ml, and was incubated at 35°C at 150 rpm. Every 24 h, 1 ml of 
the culture was suspended in 9 ml of fresh 1 µg/ml VRC-containing RPMI 1640 medium, 
for a 30-day period. Subsequently, in order to evaluate the stability of the susceptibility 
profile, this strain was subcultured daily in fresh RPMI 1640 medium without VRC for an 
additional 30 days; again, every 24 h, 1ml of the culture was suspended in 9 ml of fresh 
RPMI 1640 medium. At each daily subculture, an aliquot was stored at -70°C in 40% 
glycerol; every 2 days, a 10-µl, loopful of yeast cells was cultured in Sabouraud agar to 
check for culture contamination. Every 5 days during the 60 days of the assay, VRC 
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MIC values were determined according to the CLSI M27-A3 and M27-S4 protocols 
[174, 175]. 
 
Effect of the efflux blocker Tacrolimus (FK506) on C. krusei susceptibility profile  
 The VRC MIC values for all of the resistant C. krusei strains (clinical isolates or 
induced in vitro) were redetermined according to the CLSI M27-A3 and M27-S4 
protocols in the presence of 100 µg /ml FK506, a recognized ATP-dependent efflux 
pump inhibitor [245]. An agar disk diffusion assay was also performed using blank 
paper disks impregnated with FK506, to corroborate the results obtained with the CLSI 
protocols. Yeast suspensions of resistant C. krusei strains were prepared to an optical 
density of 0.5 McFarland standard (Densimat; bioMérieux, Marcy l’Etoile, France) and 
spread onto YPD agar plates with VRC at 4 µg/ml or without VRC. Blank paper disks 
(BBL, 6 mm; Becton, Dickinson) were impregnated with serial 10-fold dilutions of FK506 
solutions, ranging from 1,000 to 1 µg/ml, or with its solvent, dimethyl sulfoxide (DMSO) 
(Merck, Darmstadt, Germany); paper disks were applied to the inoculated agar plates. A 
plate containing only VRC at supra-MIC values was used as a control for cell viability for 
each strain. Results were read after 24 h and 48 h of incubation at 37°C. 
 
Resistance gene expression analysis 
 Total RNA extraction: C. krusei strains were incubated in YPD broth at 35°C, at 
150 rpm, until the exponential growth phase. Yeast cells were harvested by 
centrifugation at 1,610xg for 5 min at room temperature (Universal 320 R; Hettich) and 
were immediately frozen in liquid nitrogen. Total RNA was extracted using the hot acid-
phenol method, as described by Köhrer and Domdey [246]. RNA samples were 
resuspended in DNase/RNase-free water, adjusted to a final concentration of 100 ng/l, 
and stored at -70°C for later use.  
 
 Reverse transcriptase PCR (RT-PCR). Two-step real-time PCRs were 
performed. Reverse transcriptase reactions were performed as recommended by the 
manufacturer; 50 ng of RNA sample, 0.015 ng/l random primers (Invitrogen, Carlsbad, 
CA), 0.5 mM dNTPs (Fermentas, Vilnius, Lithuania), and RNase-free water up to 13 l 
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were incubated at 65°C for 5 min and then placed on ice for 1 min. Subsequently, 1x 
reverse transcriptase enzyme buffer (Invitrogen, Carlsbad, CA), 5 mM dithiothreitol 
(DTT) (Invitrogen), 1 U/l RNasin enzyme (Promega, Madison, WI), 5 U/l reverse 
transcriptase enzyme (Invitrogen), and RNase-free water were added up to a final 
volume of 20 l. The reaction tubes were incubated at 25°C for 5 min, at 50°C for 60 
min, and at 70°C for 15 min for enzyme inactivation. Reactions were carried out in a 
Mastercycler ep gradient RealPlex2 system. The cDNAs were kept at -20°C. 
 
Quantitative Real-Time PCR (qRT-PCR): Genes were amplified using the following 
primers ABC1 (GenBank accession number DQ903907) (forward, 5’ – GAT AAC CAT 
TTC CCA CAT TTG AGT – 3’ and reverse, 5’ – CATATGTTGCCATGTACA CTTCTG – 
3’),  ABC2 (GenBank accession number, AF250037) (forward, 5’ – 
CCTTTTGTTCAGTGCCAGATTG – 3’ and reverse, 5’ – GTAACC 
AGGGACACCAGCAA– 3’), ERG11 (GenBank accession number FJ445756) (forward, 
5’ – ATTGCGGCCGATGTCCAGAGGTAT – 3’ and reverse, 5’ – 
GCGCAGAGTATAAGAAAGGAATGGA – 3’), ACT1 (GenBank accession number  
AJ389086) (forward, 5' - TGGGCCAAAAGGATTCTTATG -3' and reverse, 5'-
AGATCTTTTCCATATCATCCCAG- 3') (STABVida, Lisbon, Portugal).  The quantitative 
real-time (qRT)-PCR mixture contained 1x PerfeCTa SYBR green FastMix (Quanta 
Biosciences, Gaithersburg, MD), forward and reverse primers (ABC1, ABC2, and 
ERG11, 0.9 M; ACT1, 0.5 M), 2 l of cDNA, and RNase-free water, up to a final 
reaction volume of 20 l. MgCl2 was used in the ABC2 gene reaction mixture at a final 
concentration of 1 mM. All reactions were performed in the Mastercycler ep gradient 
RealPlex2 system; parameters were chosen according to the manufacturer’s 
recommendations except for primer annealing temperatures, which were as follows: 
ABC1, 54°C; ABC2, 56°C; ERG11, 60°C; ACT1, 54°C. To check for PCR product 
specificity, a melting curve was established, with temperatures ranging from 60°C to 
95°C, for 20 min. 
  
 Data Analysis: A standard curve, containing serial 5-fold dilutions ranging from 
500 ng to 0.8 ng of RNA transcribed to cDNA, was determined in triplicate for 
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quantification and assessment of reaction efficiency for each gene. Assays were 
validated for reaction efficiencies ranging from 80% to 100%, and with a standard curve 
presenting a mean squared error higher than 0.99. The results were analyzed using 
RealPlex software (version 1.5.474; Eppendorf). Relative gene expression levels were 
calculated using REST 2009 software (Qiagen GmbH, Munich, Germany) [247], with 
the susceptible C. krusei strain as the reference sample and each resistant C. krusei 
strain as the target sample; the ACT1 gene was used to normalize levels of gene 
expression. Genes exhibiting 2-fold increases in expression were considered 
overexpressed. 
 
Statistical analysis 
 Analyses of results were performed using SPSS version 19.0. Continuous and 
paired-sample Student’s t tests were used to analyze significant differences in gene 
expression displayed by the distinct C. krusei strains; P values of <0.05 were 
considered statistically significant. 
  
Sequencing data analysis of ERG11 gene 
 Total genomic DNA was extracted as described above. The ERG11 gene (1,890 
bp) was amplified by PCR; the reaction mixture contained 1 U/µl Dream Taq DNA 
Polymerase enzyme, 1x Dream Taq DNA Polymerase enzyme buffer, 0.2 mM dNTPs 
(all from Fermentas, Vilnius, Lithuania), forward_1 (5’ – 
GGTTGTTTGTTCATTTAATGTGTGT – 3’) and reverse (5’ – 
GAAGGGGGAAAGAAAGGGAA – 3’) primers at 0.8 µM (STABVida, Lisbon, Portugal) 
and RNAse-free water up to a final volume of 25 l. All reactions were performed in a 
Mastercycler ep gradient RealPlex2 system, and reaction parameters involved an initial 
2-min denaturation step at 95ºC, 30 cycles of 95ºC for 30 s, 52ºC for 30 s and 72ºC for 
1 min,  and a final 10-min extension step at 72ºC. PCR products were treated with 
ExoSAP-IT (USB Corp., Cleveland, OH) and used as templates for the sequencing 
reactions. Sequencing was performed with the BigDye Terminator cycle sequencing 
ready reaction kit (Applied Biosystems, Carlsbad, USA) using the forward_1, forward_2 
(5’ – AACTACTGGAAAAGAGATGCTGC – 3’) and forward_3 (5’ – 
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CACTCGTGATTTACCCGTTCC – 3’) primers, at 0.8 µM final concentration. DNA 
products were purified with Sephadex G-50 Fine (GE Healthcare, Buckinghamshire, 
United Kingdom) and sequenced in an ABI Prism 3130 genetic analyzer (Applied 
Biosystems, Foster city, CA). Results were analyzed with Sequencing Analysis software 
(version 5.2; Applied Biosystems). The ERG11 gene coding sequences of the resistant 
strains were aligned with the susceptible ERG11 gene coding sequence using MUSCLE 
software/ClustalW [248]. Alignments were analyzed with BioEdit software 
(http://www.mbio.ncsu.edu/BioEdit/bioedit.html)/ ClustalW. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In vivo and in vitro acquisition of resistance to voriconazole by C. krusei 
 
- 73 - 
Results 
 
Nomenclature and susceptibility profile of C. krusei strains 
 Four C. krusei clinical isolates were selected according to the VRC MIC values 
and the collection date (more than 10 days apart), i.e., a susceptible isolate with a VRC 
MIC of 0.5 µg/ml, that was recovered from a blood culture before initiation of VRC 
therapy, designated strain SD0, and three resistant isolates with VRC MICs of 4 µg/ml.  
The latter were designated RclinD24, RclinD35, and RclinD84 according to the day of recovery 
during VRC therapy. RclinD24 was the first VRC-resistant isolate and was recovered from 
stools, while RclinD35, and RclinD84 were collected from bronchial secretions (figure 1). The 
susceptibility profile of the 4 C. krusei clinical isolates with the different classes of 
antifungals are detailed in table 1. As expected, C. krusei revealed intrinsic resistance 
to FLC. 
 
Table 1 - MIC and susceptibility profile of C. krusei clinical isolates. 
 
Strain 
identification 
Recovery site 
MIC (µg/ml)/ Susceptibility profile 
AMB B FLC VRC PSC AND CSF MCF 
SD0 Blood 0.5/S 64/R 0.5/S 0.5/S ≤0.06/S 0.5/I 0.5/S 
RclinD24 Stools 1.0/S 64/R 4.0/R ≤0.03/S ≤0.06/S 0.25/S 0.5/S 
RclinD35 Bronchial Secretions 1.0/S 64/R 4.0/R 0.06/S ≤0.06/S 0.125/S 0.25/S 
RclinD84 Bronchial Secretions 0.125/S 64/R 4.0/R 0.5/S ≤0.06/S 0.5/S 0.25/S 
 
NOTE: Antifungals: AMB B – Amphotericin B; CSF – Caspofungin; AND- Anidulafungin; MCF – Micafungin; FLC – 
Fluconazole; VRC – Voriconazole; PSC – Posaconazole; Susceptibility phenotype: S-susceptible, I- intermediate, R-
resistant. 
 
 The VRC MIC turning point to resistance of strain SD0 during the in vitro 
induction assay occurred at day 5 of exposure to VRC, corresponding to a MIC of 4 
g/ml. The VRC MIC for all C. krusei strains remained unchanged during the 55 
subsequent days of the assay (Table 2; figure 2). Selected strains were designated 
according to the day of incubation with VRC; strains obtained at days 5, 10, and 30 of 
In vivo and in vitro acquisition of resistance to voriconazole by C. krusei 
 
- 74 - 
the induction assay were named RindD5, RindD10, and RindD30, respectively. The resistant 
strain obtained after 30 days of culture in VRC-free medium was named RD60 (figure 2). 
 
 
Figure 2 - Induction of resistance to voriconazole in vitro. The timeline of the development of VRC 
resistance in a susceptible C krusei clinical isolate that was exposed daily to VRC at 1 µg/ml, with the 
respective susceptibility profiles and relative gene expression levels, is shown. ID, identification; S, 
susceptible, R, resistant. *P < 0.05   
 
Table 2 - MIC and susceptibility profile to VRC, alone and in combination with FK506 of C krusei 
strains. 
 
 
 
 
Resistance  
Strain 
ID 
VRC MIC (µg/ml)/ susceptibility profile when used with: 
No FK506 100 µg/ml  FK506 
None SD0 0.5/S 0.125/S 
In vivo acquired 
RclinD24 4.0/R 0.5/S 
RclinD35 4.0/R 0.5/S 
RclinD84 4.0/R 0.25/S 
 
In vitro acquired  
RindD5 4.0/R 0.5/S 
RindD10 4.0/R 0.5/S 
RindD30 4.0/R 0.5/S 
RD60 4.0/R 0.25/S 
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Molecular typing  
 Both REA and RAPD techniques exhibit high discriminative power, as described 
by Sancak et al and Bautista-Muñoz et al, respectively [114, 244]. All of the C. krusei 
clinical strains exhibited the same restriction pattern in REA, and the same amplification 
pattern in RAPD analysis, as shown in figure 3. Therefore, these results strongly 
indicate that the strains colonizing the leukemia patient were genetically related and 
arose from the common ancestor susceptible strain SD0.   
 
A                                         B       
  
 
 
Figure 3 - Genotyping of clinical isolates. (A) Restriction endonuclease pattern of HinfI-digested DNA of C. 
krusei clinical isolates in agarose gel electrophoresis; (B) Random Amplification Polymorphic DNA (RAPD) 
of C. krusei clinical isolates with primers OPA-18 and OPE-18. Lane   M, 1-kb DNA ladder (Metabion); lane 
1, SD0, lane 2, RclinD24, lane 3, RclinD35, lane 4, RclinD84, lane 5, Non related C krusei control strain; lane NC, 
PCR negative control. 
 
Effect of FK506 upon C. krusei susceptibility profile  
In the presence of FK506 all of the resistant strains changed to a VRC 
susceptible phenotype (Table 2). The agar disk diffusion assay confirmed the 
microdilution results; growth inhibition was found for all the resistant strains around 
  M    1     2      3     4         5   M     1      2       3      4      NC      M    1       2       3       4     NC 
        Primer OPA -18                                 Primer 
OPE -18 
In vivo and in vitro acquisition of resistance to voriconazole by C. krusei 
 
- 76 - 
disks containing the two highest FK506 concentrations (100 and 1000 g/ml) in the 
presence of VRC at 4 g/ml (figure 4, B and D). Susceptible strain SD0 was unable to 
grow in the presence of VRC at 4 g/ml. The FK506 solvent, DMSO, did not impair the 
growth of the strains, and neither did FK506 alone (figure 4, A and C).  
 
 
Figure 4 - FK506 disk diffusion assay. Resistant C. krusei strains were grown on YPD medium and paper 
disks impregnated with serial 10-fold dilutions of FK506, ranging from 1000 to 1 g/ml,  without VRC (A and 
C), or VRC at 4 g/ml (B and D). RclinD24 (A and B) and RindD30 (C and D) are shown as representative 
examples of C. krusei strains with in vivo and in vitro induced resistance, respectively. S1, 100%, S2, 10%: 
disks impregnated with DMSO at different concentrations. 
 
Resistance gene expression analysis  
The analysis of gene expression in Rclin strains with real-time PCR showed 
significant overexpression of the ABC1 gene, in comparison with the susceptible SD0 
strain (figure 1; figure 5A). This was not the case for the other two associated resistance 
genes, ABC2 and ERG11. Only the RclinD35 strain presented a significant increase in 
ERG11 gene expression. Similar ABC1 gene expression profiles were registered for all 
of the Rind strains and the RD60 strain, i.e., during the induction protocol, significant 
increases in the relative expression of the ABC1 gene were documented (figure 1; 
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figure 5B). Variations in ABC2 gene expression were not significant for any of these 
strains. ERG11 relative gene expression levels demonstrated significant increases in 
the RindD5 and RindD10 strains.  
 
A 
  
B
 
In vivo and in vitro acquisition of resistance to voriconazole by C. krusei 
 
- 78 - 
 Figure 5 - ABC1, ABC2 and ERG11 relative gene expression levels in resistant C. krusei clinical isolates 
(A) and resistant strains induced in vitro (B). ABC1, ABC2 and ERG11 gene expression levels were 
quantified and normalized relative to the housekeeping gene, ACT1; relative gene expression levels were 
calculated as ratios between each C. krusei resistant strain and the SD0 isolate; * P< 0.05.  
 
 
ERG11 gene sequencing analysis 
Several ERG11 gene mutations were reported previously to be associated with 
azole resistance in C. albicans [196]; therefore, the C. krusei ERG11 gene was 
sequenced in our strains. Two different types of mutations were found. All of the 
susceptible and resistant C. krusei strains presented a heterozygous alteration at 1,389 
bp (TC) (overlapping signals in the electropherogram data), resulting in synonymous 
single-nucleotide polymorphisms (SNPs). Notably, RclinD35 and RclinD84 presented a 
missense mutation at position 418 bp (TC), yielding a TyrHis amino acid change. 
This point mutation had not been described previously for C. krusei strains. 
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Discussion 
 
C. krusei is one of the leading agents of candidemia among patients with 
hematologic malignancy. In this study, the 4 consecutive C. krusei clinical isolates 
obtained from the leukemia patient during VRC therapy were evaluated for their 
susceptibility profiles and genetic relationships. Although they displayed distinct 
susceptibility profiles, these isolates were genetically related (figure 3). The initial 
colonizing strain SD0 changed from a VRC-susceptible phenotype to a stable VRC-
resistant phenotype during a long period of VRC therapy. Thus, we were confronted 
with a case of resistance to VRC acquired in vivo. It should be stressed that the 
bioavailability and concentrations of the bioactive drug in vivo are highly variable due to 
several factors, such as different infection sites, concomitant therapies, and the status 
of the host immune system [152]. The C. krusei clinical isolates might have been in 
contact with subinhibitory concentrations of the antifungal agent for a long period, which 
were not sufficient to eliminate the organism but were enough to stimulate stress 
adaptation mechanisms leading to resistance. Therefore, a susceptible C. krusei isolate 
(strain SD0) was later continuously exposed to VRC in vitro, in order to compare the 
development of resistance in vivo and in vitro.  
FK506 was used as a first approach to explore the mechanisms of resistance to 
VRC displayed by C. krusei strains. It was previously described as being able to reverse 
multidrug resistance in different types of eukaryotic cells, due to the blockade of 
ATPdependent efflux pumps, namely, human P-glycoprotein, C. albicans Cdr1p/Cdr2p, 
and more recently C. krusei Abc1p [16, 245, 249]. The synergistic effects of FK506 and 
VRC that occurred with all of the resistant C. krusei strains, in both the microdilution and 
test disk assays, clearly showed that efflux pumps contributed to the VRC-resistant 
phenotype in both Rclin and Rind strains. 
Several genes have been reported to be involved in C. krusei resistance to 
azoles. For example, according to Katiyar and Edlind, efflux pumps from the ABC family 
of proteins are crucial for resistance to azoles [211]; in contrast, Guinea et al. concluded 
that the MDR family of proteins plays a minor role in C. krusei resistance to azoles 
[212]. ERG11 gene upregulation in C. krusei strains in response to azole treatment (3 h 
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of incubation with FLC at 9 µg/ml) was described [250]. Taken this into account, 
molecular insights were needed to corroborate the hypothesis that VRC resistance is 
mostly associated with the activity of efflux pumps and to exclude other resistance 
mechanisms.  
This is the first work to address the quantification of target gene expression by 
real-time PCR in wild-type resistant isolates, i.e., not genetically manipulated strains. 
The gene expression profile described herein for all of the resistant C. krusei strains 
(figure 5) strongly suggests that the acquisition of long-term resistance is mostly 
associated with the ABC1 gene. Similar findings were previously described by Holmes 
et al. for C. albicans and by Bennett et al. for Candida glabrata, i.e., Cdr1p efflux activity 
contributes more to FLC resistance than Cdr2p [251, 252]. However, our C. krusei RindD5 
strain is a controversial case since neither ABC1 nor ABC2 genes are overexpressed. 
Initially, exposure to VRC induces increases in ABC2 gene expression, overcoming 
ABC1 gene expression. We hypothesize that ABC2 can be activated more rapidly, 
although transiently. For long-term VRC tolerance, yeasts clearly prefer to activate the 
Abc1p efflux pump, which seems to be more efficient in antifungal expulsion. On the 
other hand, other genes encoding ATP-dependent efflux transporters may be present in 
C. krusei, such as a CgSNQ2 homologous gene that was described as an azole-
associated resistance gene in C. glabrata [253]. Although it has been sequenced, the C. 
krusei genome is not yet completely annotated; thus, other transporter genes were not 
assessed. In addition, Lamping et al. incubated C. krusei strains for up to 4 h with 
different antifungals, including VRC, and no significant increases in ABC1 mRNA levels 
were recorded [16]. In our case, the ABC1 gene was significantly overexpressed in C. 
krusei strains after only 10 days of in vitro exposure (strain RindD10) or 24 days of VRC 
therapy (strain RclinD24). Together, these facts clearly show that the ABC1 gene is 
upregulated after an extended period of antifungal exposure, playing a late role in the 
development of resistance. After being triggered, however, ABC1 gene overexpression 
correlates with a stable resistant phenotype, playing a definite role in long-term VRC 
resistance even in the absence of azoles (strain RD60) (figure 5B). ERG11 gene 
overexpression seems to be relevant in the development of VRC resistance only at an 
early stage, as an initial adaptation mechanism (figure 5). Later, other distinct 
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mechanisms, such as the acquisition of point mutations, predominate. The point 
mutation described herein is definitely associated with VRC resistance in C. krusei, 
since the same type of mutation was already reported to be associated with azole 
resistance in C. albicans [254]. Thus, we were confronted with the fact that C. krusei 
acquired multiple resistance mechanisms not previously described for this fungal 
pathogen. Such a finding is of medical relevance in considering therapeutic protocols; a 
susceptible isolate can develop resistance to VRC during a therapeutic regimen. On the 
other hand, the heterozygous alteration detected (T1389C), which is located outside the 
azole binding site, according to previously published data, was found in both 
susceptible and resistant strains [255]. This alteration corresponds to synonymous 
SNPs, whose repercussions remain to be determined. These findings are in accordance 
with previous results by Lamping et al., who found several synonymous SNPs in the 
ERG11 gene sequence, including the one detected by us [16]. The results presented 
emphasize that prolonged therapy with azole antifungals can lead to resistant clones, 
which can ultimately spread and colonize other susceptible hosts.  
In this study, we elucidated for the first time the presence of multiple 
concomitant resistance mechanisms in resistant C. krusei strains induced in both in vivo 
and in vitro assays. We demonstrated the relevant role that efflux activity plays as a 
mechanism of resistance to VRC, as well as the acquisition of a missense point 
mutation in the target enzyme Erg11p. The set of C. krusei strains described herein 
depicts the evolutionary process of resistance acquisition both in vitro and in vivo, being 
a valuable tool for the study of antifungal resistance in C. krusei. 
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Abstract   
  
 The treatment of candiduria is always a concern in the clinical practice, due to 
the low level of antifungal drug reaching the urinary tract. A patient submitted to a 
kidney transplant was diagnosed with candiduria involving C. krusei and treated with 
VRC 200mg/2x day for 20 days.  Five C. krusei isolates recovered from the urine were 
selected: one susceptible before VRC therapy (MIC 0.25 g/ml), two resistant during 
VRC therapy (MIC 4.0 g/ml) and two susceptible after VRC discontinuation (MIC 0.25 
g/ml). Clinical isolates were all genotyped using both intergenic repeat-PCR patterns 
(CKRS-1) and CKTNR microsatellite analysis, confirming their genetic relationship. 
Therefore, we were dealing with a case of development of transient resistance in vivo. 
Based on these results, we intended to corroborate the hypothesis that exposure to 
suboptimal VRC concentrations could lead to VRC resistance. We incubated eight 
independent clinical strains of C. krusei with VRC 0.001 g/ml, during 30 days. The 
MICs to VRC of these strains ranged from 2 to 8 g/ml, corresponding to a resistant 
phenotype. In the presence of VRC and the efflux pump blocker FK506, the susceptible 
phenotype was restored in the microdilution assay and inhibition of growth of all the 
VRC-resistant isolates occurred in the agar disk diffusion  
assay. In order to uncover the mechanisms of resistance to VRC, efflux pumps encoded 
by ABC1 and ABC2 genes and the target enzyme of azoles Erg11p, encoded by 
ERG11 gene, were investigated.  ABC1 and ERG11 genes were overexpressed in the 
clinical isolates resistant to VRC and decreased to a basal level of expression in post-
therapy isolates. The C. krusei strains incubated in vitro with small doses of VRC 
presented at least one of the resistance genes significantly overexpressed, mostly 
ABC1 and ERG11 genes and different alterations in ERG11 gene sequence. 
Interestingly, the strain presenting the lowest level of gene expression associated to 
resistance genes displayed a homozygous nonsynonymous mutation at position 418bp 
(T C), translating into a different aminoacid TyrHis.  
In conclusion, although the effective therapeutic concentration of antifungal 
reaching the bladder is usually low, the acquisition of resistance to antifungal drugs can 
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be achieved. The mechanisms of resistance studied in the C. krusei strains resistant 
strains were all present and in some strains complement each other. 
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Background 
  
 Candida species appear to be unique in their ability to both colonize and cause 
invasive disease in the urinary tract [256]. Candiduria is defined as a superficial 
infection with Candida spp., therefore does not belong to the group of IC [31, 257, 258]. 
Candiduria is asymptomatic in up to 96% of the patients and it is not considered a 
serious clinical condition [61]. However, it can be problematic in patients admitted to 
ICU namely, immunocompromised patients with underlying serious diseases, in patients 
with permanent urinary catheters, with diabetes or with altered bacterial flora due to 
intensive use of broad spectrum antibiotics [61, 62, 75, 259, 260]. Candida albicans is 
the most important and commonly isolated yeast among Candida species followed by C. 
glabrata and C. tropicalis [61, 76, 261, 262]. In this non-albicans group, C. krusei is not 
frequently isolated [263]. Colonization and invasion of the urinary tract can occur in 
either an antegrade fashion from the bloodstream or retrograde via the urethra and 
bladder, being the latter the most common route of infection. The presence of Candida 
species in the urine may be due to different clinical conditions: pyelonephritis or cystitis, 
hematogenous seeding of the kidney cortex due to disseminated candidiasis or 
colonization of the bladder, perineum or indwelling urinary catheter.  However, there is 
some concern about candiduria since it can be the spark to candidemia in critically ill 
patients. Also, when fungus ball form, there is a strong probability of biofilm formation 
allowing the persistence of the organism in the host [70]. One of the big concerns 
related to candiduria is the therapeutic decision of the physicians [76]. This is probably 
due to the fact that no diagnostic tools are available to readily differentiate between 
candidal UTI, colonization or contamination in the ICU setting. The IDSA (Infectious 
Diseases Society of America) has defined indications for therapy of candiduria in late 
2003 in the following groups: infants with very low birth weights, patients undergoing 
genitourinary procedures, patients with neutropenia, renal transplant recipients and 
symptomatic patients. Several classes of antifungals are available but none of them is 
the best suited antifungal. Fluconazole is the first choice as it is excreted unchanged by 
the kidneys, KTC and ITC are poorly excreted in the urine and VRC and PSC achieve 
minimal urinary excretion, AMB B is very nephrotoxic, and all echinocandins are 
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associated to extremely poor glomerular filtration or tubular secretion in vivo, as 2–3% 
of active drug is eliminated in the urine, resulting in subtherapeutic concentrations in the 
urine [61, 77, 78, 80].  
 We describe in this work a case of candiduria by C. krusei in a patient submitted 
to a kidney transplant and under VRC therapy. It was registered the transient 
acquisition of resistance to VRC in vivo. Two major mechanisms associated to azole 
resistance have been described in C. krusei: the presence of efflux pump proteins 
(Abc1p and Abc2p), and a diminished sensitivity of the azole antifungals to the enzyme 
cytochrome P450 lanosterol 14-demethylase, Erg11p, encoded by ERG11 gene.  
Efflux pump proteins in C. krusei belong to the ABC transporter family, encoded by 
ABC1 and ABC2 genes which promote the extrusion of the antifungal drug from the cell, 
reducing the cellular drug accumulation. Candida krusei is intrinsically resistant to FLC 
due to alterations in Erg11p binding site [201, 211]. Recently, one mutation associated 
to resistance was described by our team in ERG11 gene in C. krusei strains resistant to 
VRC at position 418 bp (T C) translating into a TyrHis amino acid change [264]. 
Acquisition of resistance in vivo was replicated in vitro in the presence of very low 
concentrations of VRC. We intended to uncover the mechanisms of resistance that 
developed in C. krusei strains in vitro and in vivo.  
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Material and Methods 
 
Case report and clinical C. krusei strains isolation 
 A 20-year-old woman was hospitalized in December 2003, for acute renal failure 
secondary to rhabdomyolisis, induced by atorvastatine (Tahor®). She presented with a 
probable evolution of a previously undiagnosed chronic renal insufficiency, associated 
with urological malformation and familial hypercholesterolemia. In November 2005, 
renal transplantation was performed and immunosuppressive treatment (tacrolimus, 
mycophenolate mofetil and corticoids) was given. Twelve days after transplantation, 
bacteraemia due to Escherichia coli occurred probably due to a contamination of the 
solution for graft kidney preservation. She was administered ceftriaxone and 
ciprofloxacine. At day 18 of transplantation, she presented with an aneurysm dissection 
of renal artery associated with hematoma. Therefore, the surgeons had to perform 
hypogastric autograft and distal anastomosa in hilus of renal graft, resulting in the 
preservation of the graft. Pre-renal hematoma was progressively resolved with 
antibiotics. At day 25th after transplant, the first episode of candiduria occurred. At day 
44th after transplant, oral FLC 200 mg/day was implemented. However, at day 44 of 
kidney transplantation, FLC stopped and began to take oral VRC 200 mgx2/day, 
prescribed for 20 days mainly for graft preservation (prophylaxis), despite probable low 
urinary diffusion associated with low expected efficacy against candiduria. After 82 days 
of renal transplant she was admitted to the emergency with fever, probable dissecting 
aneurysm of renal artery at CT-scan. Therefore, she was submitted to resection of 
kidney graft and prescribed antibiotics and intravenous AmB 1 mg/kg/day for 3 weeks. 
Since the first episode of C. krusei candiduria several C. krusei isolates were recovered 
and five were selected. The C. krusei isolates recovered before the VRC treatment 
presented a susceptible phenotype, those recovered during VRC treatment presented a 
resistant phenotype and those isolates recovered after the withdraw of the antifungal 
turned to a susceptible phenotype.  
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Candida krusei clinical isolates genotyping 
All the clinical isolates recovered from the patient submitted to kidney transplant 
were evaluated for their genetic relatedness, in order to confirm whether the patient 
harbored the same C. krusei strain or not during her follow-up.  
 
 Total genomic DNA extraction. The protocol was performed as next described. 
Briefly, C. krusei isolates were cultured in 10 ml of YPD liquid medium, overnight at 
35ºC, 150 rpm, and subsequently collected at room temperature by centrifugation 
(Hettich, Universal 320 R, 1610xg, 10min). Total DNA was extracted using 
phenol:chloroform:isoamyl alcohol 25:24:1 (Sigma-Aldrich, Munich, Germany), 
precipitated with 100% ice-cold ethanol (Applichem, Darmstadt, Germany), and 
redissolved in 200 µl of TE buffer. The DNA was treated with 20 µg of RNase 
(Applichem, Darmstadt, Germany), incubated at 37ºC for 1 h. For final precipitation, 20 
µl of 4 M ammonium acetate, pH 4.8 (Sigma-Aldrich, Munich, Germany) and 600 µl of 
ice-cold 100% ethanol (Applichem, Darmstadt, Germany) were added and samples 
were incubated overnight at – 20ºC. DNA samples were resuspended in TE buffer 1x, 
concentration adjusted to 2.0-2.5 g/l and stored at -20ºC for later use.  
 
Genotyping analysis: (i) PCR CKRS-1 analysis. Amplification was performed on 
10 ng of genomic DNA with primers Arno1 (5’-GCCAACACATACATACCTT-3’) and 
Arno2 (5’-GGTAGGATACTAACCACAGC-3’) as described by Carlotti et al [265]. 
Reaction were performed in 50-µL mixtures containing with 100 µM of each dNTP 
(dNTPset, MBI Fermentas, Vilnius, Lithuania), 0,2 µM of each primer (Genset SA, Paris, 
France), 1X Buffer and 1,5 U REDTaq-PolymeraseTM (SigmaTM, St Louis, MO, USA).  
The amplified fragments were visualized after separation by agarose gel 
electrophoresis with ethidium bromide (0.5µg/mL) staining. PCR amplification  
parameters included an initial denaturation step for 4 min at 92°C, 32 cycles of 
annealing for 30s at 55°C, extension for 2 min at 72°C, and denaturation for 30s at 
92°C followed by final extension at 72°C for 10 min [265].PCR products were visualized 
and compared for amplification pattern similarities using electrophoresis at 140 V for 4 h 
on a 1% agarose gel, and staining with ethidium bromide solution 0.5 mg/ml 
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(Applichem, Darmstadt, Germany). PCR amplification products were analyzed using the 
Gel Logic 100 Imaging System Software (Kodak). Three unrelated C. krusei clinical 
isolates of distinct patients were used as a control. 
(ii) Microsatellite CKTNR analysis: Assessment of CKTNR polymorphism was 
performed by fragment size analysis, using primers CKTNR3 and CKTNR5 as 
described by Shemer et al [266]. Primers CKTNR3 was 5’ labelled with 
hexachlorocarboxyfluorescein (HEX). Reaction were performed in 20-µL mixtures 
containing 30 ng of genomic DNA, 200 µM of each dNTP (dNTPset, MBI Fermentas, 
Vilnius, Lithuania), 0,5 µM of each primer (Genset SA, Paris, France), 1X Buffer and 0,5 
U REDTaq-PolymeraseTM (SigmaTM, St Louis, MO, USA). Amplicons were sized using 
capillary electrophoresis on ABI Prism 3130.  Results were expressed with respect of 
haplotype denomination described by Shemer et al., using C. krusei strain CBS 573 as 
control [266]. 
 
In vitro generation of VRC-resistant derivatives of C. krusei after VRC exposure 
 Eight independent clinical strains of C. krusei susceptible to VRC were isolated 
from several biological products of different patients with different underlying diseases, 
not submitted to VRC therapy (table 1). The strains were grown in brain-heart infusion 
(BHI) broth medium containing 0.001 g/ml of VRC, with daily subcultures in fresh BHI-
VRC for 30 days, in order to obtain derivatives resistant to VRC. Briefly, every 24 h, 1 
ml of the culture was suspended into 9 ml of fresh BHI broth medium; every 2 days a 10 
l loopful of yeast cells was cultured in Sabouraud agar plates to check for culture 
contamination. 
 
Susceptibility Testing and Effect of the efflux blocker FK506 (Tacrolimus)  
Voriconazole (Pfizer, Groton, CT), PSC (Schering- Plough; New Jersey, USA)   
and ITC (Sigma Aldrich, Saint-Quentin, France) antifungals stock solutions were 
prepared according to the M27-A3 protocol and M27-S4, the fourth informational 
supplement, by the CLSI and maintained in stock solution at -70°C until use. 
Susceptibility profile of the C. krusei clinical isolates and the strains obtained before 
(D0) and after 30 days (D30) of incubation with VRC were performed for the antifungals 
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VRC, PSC and ITC, according to CLSI M27-A3 protocol and M27-S4, the fourth 
informational supplement, by the Clinical Laboratory for Standards Institute (CLSI) ) 
[174, 175]. 
The susceptibility profiles to VRC of the C krusei isolates were in accordance to 
the following MIC values: susceptible whenever MIC < 0.5 µg/ml, susceptible dose 
dependent whenever MIC=1.0 µg/ml and resistant whenever MIC > 2.0 µg/ml. The 
susceptibility profiles to PSC of the C krusei isolates were in accordance to the following 
MIC values: susceptible whenever MIC < 0.5 µg/ml, susceptible dose dependent 
whenever MIC=1.0 µg/ml and resistant whenever MIC > 2.0 µg/ml.  The susceptibility 
profiles to ITC of the C krusei isolates were in accordance to the following MIC values: 
susceptible whenever MIC < 0.125 µg/ml, susceptible dose dependent whenever MIC 
ranges between 0.25-0.5µg/ml and resistant whenever MIC > 1.0 µg/ml. Visual readings 
were performed after 24h and 48h of incubation, according to the same protocols. C. 
krusei type strain ATCC 6258 from the American Type Culture Collection was used as 
control, as recommended [174, 175]. 
 
Microdilution Assay: The reversion of multidrug resistance was described in 
different types of cells, including Candida spp when in the presence of antifungals 
azoles and FK506 (Tacrolimus), a blocker of ATP dependent efflux pumps [245]. 
Therefore, MICs of VRC for C. krusei strains were re- determined, according to CLSI 
M27- A3 and M27-S4 protocols, in the presence of Tacrolimus (FK506) 100 g/ml.  
 
Agar disk diffusion assay: An agar disk diffusion assay was also performed 
using FK506 to corroborate the results obtained with the CLSI protocol: yeast 
suspensions of the distinct resistant strains (0.5 McFarland standard; Densimat, 
Biomerieux, France), were spread each onto YPD agar plates containing VRC at a 
supra-MIC value, according to the MIC value of each strain and without VRC. Blank 
paper disks, 6mm (BBL, Becton Dickinson France S.A.), were impregnated with serial 
10-fold dilutions of FK506 solutions, ranging from 1000 to 1 g/ml, and with its solvent, 
dimethyl sulfoxide (DMSO, Merck). Dried paper disks were applied onto the inoculated 
agar plates. A plate containing only VRC at the supra-MIC values was used as a control 
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for cell viability for each strain. The agar plates were incubated at 37ºC, and the results 
were registered after 24h and 48h.  
 
Resistance gene expression analysis 
 Total RNA extraction: Selected C. krusei strains were incubated in YPD broth at 
35ºC, 150 rpm, until exponential growth phase; yeast cells were harvested by 
centrifugation at room temperature, (Hettich, Universal 320 R, 1610xg, 5 min), 
immediately frozen in liquid nitrogen. Total RNA was extracted using the hot acid 
phenol method, as described by Köhrer & Domdey [246]. RNA samples were 
resuspended in DNase/ RNase-free water, concentration adjusted to a final 
concentration of 100 ng/l and stored at -70ºC for later use.  
 
Reverse transcriptase PCR (RT-PCR). Two-step real-time PCR reactions were 
performed. Reverse transcriptase reactions were performed as previously described by 
Ricardo et al [264].  The cDNAs were kept at -20ºC until later use. 
 
Quantitative Real-Time PCR (qRT-PCR): ABC1, ABC2 and ERG11 genes were 
amplified using the primer pairs described by Ricardo et al [264]. qRT-PCR reaction 
mixture contained: SensiFAST SYBR No-Rox Mix 1x (Bioline, Taunton, MA, USA), 
primers forward and reverse (ABC1, ABC2, ERG11 0.9 M and ACT1 0.5 M), 2 l of 
cDNA and RNAse-free water, up to a 20 l final reaction volume. MgCl2 was used in 
ABC2 gene reaction mixture at a final concentration of 1mM. All reactions were 
performed in the Mastercycler epgradient Realplex2; parameters were chosen 
according to the manufacturer’s recommendations, including primer annealing 
temperature, 60ºC. To check for PCR product specificity, a melting curve was 
established, i. e., temperature ranging from 60ºC to 95ºC, for 20 min. 
 
 Data Analysis: A standard curve was inserted, in triplicate, containing serial five-
fold dilutions ranging from 500 ng to 0.8 ng of RNA transcribed to cDNA, as previously 
described by Ricardo et al [264]. The results were analyzed using the program software 
Realplex version 1.5.474, from Eppendorf. Relative target gene expression levels were 
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calculated using the software REST 2009 (QIAGEN GmbH, Munich, Germany), being 
the susceptible C. krusei strain the reference sample and each resistant C. krusei strain 
the target sample; ACT1 gene was used to normalize gene expression levels [247]. 
Target genes exhibiting a 2-fold increase in expression and with a p value <0.05 
associated were considered significantly overexpressed.  
 
Statistical analysis 
 Result analysis was performed using the software SPSS (Statistical Package for 
Social Sciences) version 19.0. Continuous and paired sample Student's t-test was used 
to analyse significant differences between target gene expression displayed by the 
distinct C. krusei strains; a p value <0.05 was considered statistical significant. 
 
Sequencing data analysis of ERG11 gene 
 ERG11 gene was sequenced in all selected C. krusei strains in order to 
look for mutations that could be associated to VRC resistance.  
 
Total genomic DNA extraction was performed as previously described in this 
section. 
 
 ERG11 gene sequencing reactions and analysis. ERG11 gene (1890 bp) was 
amplified by PCR according to the protocols previously described by Ricardo et al [264]. 
PCR products were treated with ExoSAP-IT (USB Corporation, Cleveland, USA) and 
used as template for the sequencing reactions. Sequencing was performed with a 
BigDye Terminator cycle sequencing ready reaction kit (Applied Biosystems, Carlsbad, 
USA) using primers forward_1, forward_2 and forward_3, as previously described by 
Ricardo et al [264]. DNA products were purified with Sephadex G-50 Fine (GE 
Healthcare, Buckinghamshire, United Kingdom) and sequenced in an ABI Prism 3130 
genetic analyser (Applied Biosystems, Foster city, USA). Results were analysed with 
Sequencing Analysis software, version 5.2 from Applied Biosystems. The ERG11 gene 
coding sequences of the resistant strains were aligned with the susceptible ERG11 
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gene coding sequence using MUSCLE software/ClustalW [248]. Alignments were 
analyzed in BioEdit software (http://www.mbio.ncsu.edu/BioEdit/bioedit.html)/ ClustalW. 
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Results 
 
Candida krusei strains designation and susceptibility profiles 
 Five C. krusei clinical isolates were selected and designated according to their 
susceptibility profile and the time of recovery, respectively, during VRC therapy of the 
patient: susceptible isolate CkB.VRC (isolated Before VRC therapy), resistant isolates 
CkD.VRC9 and CkD.VRC16 (isolated During VRC therapy, 9th and 16th day), susceptible 
isolates CkA.VR10 and CkA.VRC18 (isolated After VRC discontinuation, 10th and 18th days). 
Timeline of isolation and susceptibility profiles of each of the C. krusei clinical isolates 
are detailed in figure 1. 
 
 
Figure 1 - In vivo induction of resistance to voriconazole. (a) Timeline of the renal transplant procedure, 
antifungal therapy and C. krusei clinical isolates recovered from the kidney transplant patient and their 
respective susceptibility profile; (b) Genotyping of C. krusei clinical isolates. 1- CkB.VRC, 2- CkD.VRC9, 3- 
CkD.VRC16; 4- CkA.VRC10, CkA.VRC18, NRS 1-3 – Non related isolates, M – Molecular weight; (c) Relative gene 
expression profile of ABC1, ABC2 and ERG11 genes for the C. krusei clinical isolates; *p < 0.05.  
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 An increase in the MIC to VRC was registered after 9 days of VRC therapy, the 
isolates achieving a resistant phenotype (CkD.VRC9 and CkD.VRC16); however when the 
drug was withdraw the MIC value turned to the initial values and consequently the initial 
susceptible phenotype (CkA.VR10 and CkA.VRC18). In the case of ITR the first isolates were 
already resistant but in the presence of VRC the MIC value increased even more but 
decreased after its removal. No significant variation occurred in the MIC value of PSC 
which only increased to values related to a SDD phenotype. The hypothesis that the 
same C. krusei strain was colonizing our transplanted patient was corroborated by the 
genotyping technique. All the isolates presented with the same CKRS-1 electrophoretic 
pattern (Fig. 1, panel b) and the same allelic CKNTR microsatellite profile, i.e. profile e-
f/d, according previously described nomenclature [266]. Therefore, all C. krusei isolates 
from our patient were clonal, despite presenting different susceptibility profiles. 
Concerning the strains used for experimental VRC exposure and their in vitro 
induced derivatives, they were randomly numbered and designated according to the 
day of incubation with VRC, i.e., the initial susceptible C. krusei strains obtained before 
incubation with VRC were referred as D0 and their derivatives after 30 days of 
incubation with VRC were referred as D30. Therefore, we have available the initial 
strains and their derivatives: Ck1D0 and Ck1D30, Ck8D0 and Ck8D30, Ck21D0 and Ck21D30, 
Ck24D0 and Ck24D30, Ck32D0 and Ck32D30, Ck34D0 and Ck34D30, Ck40D0 and Ck40D30, 
Ck42D0 and Ck42D30. Susceptibility profiles are detailed in Table 1. At day 30 of 
incubation with VRC, all the derivatives presented a resistant phenotype to VRC, with 
the MIC values ranging from 2 g/ml to 8g/ml and ITC with the MIC values ranging 
from 1 g/ml to 16 g/ml. 
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Table 1 – MIC, susceptibility profile, ABC1, ABC2 and ERG11 relative gene expression profile 
and ERG11 gene sequence alterations of C. krusei strains induced in vitro. 
 
 
 
Effect of efflux blocker FK506 (Tacrolimus)  
 In the microdilution assay the presence of the efflux blocker FK506 lowered the 
MIC values to VRC in all the resistant strains up to 7 fold as it was the case of the C. 
krusei strain Ck21D30. Therefore, all the resistant strains displayed a susceptible 
phenotype in the presence of FK506, with MIC values decreasing from 2-fold up to 7-
fold (Table 2).  
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Table 2 - MIC and susceptibility profiles to VRC alone and in combination with FK506 of C. 
krusei strains. 
 
 
Resistance  
VRC MIC (µg/ml)/ susceptibility profile when used with: 
Strains ID No FK506 100 g/ml FK506 
In vivo acquired 
CkD.VRC9 4.0/R 0.125/S 
CkD.VRC16 4.0/R 0.125/S 
In vitro acquired 
(D30 strains) 
Ck1 2.0/R 0.25/S 
Ck8 2.0/R 0.06/S 
Ck21 8.0/R 0.06/S 
Ck24 4.0/R 1.0/SDD 
Ck32 2.0/R 0.125/S 
Ck34 4.0/R 0.125/S 
Ck40 2.0/R 0.06/S 
Ck42 4.0/R 0.25/S 
 
 
 Concerning the agar disk diffusion assay, all the strains assayed presented 
growth inhibition (although variable in their extent of inhibition) around the disks 
impregnated with the highest concentration of FK506, in the presence of VRC at MIC 
values. Besides, neither FK506 alone nor DMSO, the FK506 solvent, inhibited the 
growth of the C. krusei strains.  
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Figure 2 - FK506 agar disk diffusion assay: resistant C. krusei strains were grown on YPD medium and 
paper disks impregnated with serial 10-fold dilutions of FK506, ranging from 1000 to 1 g/ml (FK506 disks - 
left column) and DMSO (S1 – 100%, S2 – 10%) and in the presence of VRC 4 g/ml (VRC 4 µg/ml + FK506 
disks- right column). (a) C. krusei resistant clinical isolates recovered from the kidney transplant patient; (b) 
C. krusei resistant strains induced in vitro, after incubation with VRC.     
 
Resistance gene expression analysis  
 ABC1, ABC2 and ERG11 gene expression, for the different groups of strains is 
detailed in Figure 3 (see also figure 1 and table 1).  The gene expression profile of the 
different C. krusei clinical isolates CkD.VRC9 and CkD.VRC16 is in accordance to their 
susceptibility profile, i.e. there is a significant increase in the expression of the 
resistance genes ABC1 and ERG11: C. krusei strain CkD.VRC9 ABC1 p= 0.007, ERG11 
p= 0.001, CkD.VRC16 ABC1 p= 0.003, ERG11 p= 0.009. Conversely, ABC2 gene was not 
overexpressed in these strains. The post-therapy susceptible isolates CkA.VR10 and 
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CkA.VRC18 presented basal gene expression level for all genes, similar to the reference 
susceptible isolate CkB.VRC, which was in accordance to their susceptibility profile. 
 Interestingly, the C. krusei strains incubated in vitro with small doses of VRC 
presented different gene expression profiles. Except for strains, Ck24D30, Ck34D30 and 
Ck40D30 all the remaining strains D30 present at least one of the resistance genes 
significantly overexpressed when compared to the respective susceptible strain - D0. 
The most remarkable increase in both ABCs genes was registered in Ck21D30 strain, 
being also the strain with the highest MIC value to VRC.     
 
A 
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B
  
Figure 3 - ABC1, ABC2 and ERG11 relative gene expression level in C. krusei resistant clinical isolates (A) 
and resistant in vitro induced strains (B). ABC1, ABC2 and ERG11 gene expression level was quantified 
and normalized relative to the housekeeping gene, ACT1; relative gene expression level was calculated as 
a ratio between each C. krusei resistant strain and the respective susceptible isolate; * p< 0.05.  
 
Sequencing analysis of ERG11 Gene 
 Several ERG11 gene mutations have been previously described to be 
associated to azole resistance in C. albicans [196] therefore, we sequenced C. krusei 
ERG11 gene in the selected strains. 
 Candida krusei strains induced in vitro presented different alterations in ERG11 
gene sequence detailed in table 1. All the susceptible and resistant C. krusei strains 
from both groups of strains presented heterozygous alterations at 642bp (CT) and 
1389bp (TC), all of them resulting in synonymous SNPs. It should be highlighted the 
homozygous nonsynonymous mutation at position 418 bp (T C), translating a 
different amino acid TyrHis in strain Ck24D30, which presented the lowest level of 
gene expression  associated to the resistance genes studied.  
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Discussion 
  
 Candiduria cases are usually not considered serious clinical situations because 
patient’s life is not at risk. However, the particular case of the patient submitted to a 
kidney transplant triggered our interest once it involved an unusual acquisition of 
resistance as a result of VRC therapy. Management of candiduria involves many 
uncertainties in the indication for antifungal therapy [61, 267]. Therapeutic approaches 
for candiduria are very controversial due to the difficulty in evaluating its clinical 
importance, i.e., if the presence of Candida in the urine reflects infection or colonisation 
[31, 62, 74, 75, 76].  Empirical therapy refers to the treatment of high-risk hosts with 
symptoms of disease, even in the absence of positive cultures or other clinical 
evidences [53]. However, even when antifungal therapy is applied the concentration 
reaching the urinary tract is very small, not reaching an effective dose for treatment. In 
the clinical case presented in this study most certainly the concentration of VRC was 
not effective for the treatment but it was enough to induce resistance in vivo. Also, this 
clinical case was an example of therapeutic errors due to empirical therapy since FLC 
was administrated to the patient when C. krusei strains were responsible for candiduria. 
One possible explanation can be the time of interval between the isolation of the 
pathogenic yeast and its identification. As soon as it was identified the therapy was 
changed to another azole. It was not recommended at the moment to use AMB B due to 
its nephrotoxicity. VRC is not commonly used in this clinical conditions however, since 
the patient was a transplant recipient with a high risk of rejecting the new transplant (the 
2nd transplantation), the aim of the antifungal treatment was first to protect the 
parenchyma of the kidney transplant from Candida infection and then to treat 
candiduria. According to figure 1, the strain colonizing the urinary tract developed a 
resistant phenotype after 9 days of VRC therapy and maintained it during the antifungal 
treatment for additional 7 days - CkD.VRC9 and CkD.VRC16, respectively. When VRC 
treatment was discontinued the same strain turned susceptible as shown by the 
genotyping assays, figure 1 panel (b). We can conclude that the C. krusei isolate 
suffered a selective pressure, developing resistance and activitating the efflux pumps. 
However, when the treatment stopped, along with the selective pressure the strain no 
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longer needed to actively maintain the efflux activity. Anyway the patient was under a 
risk situation because the resistant strains could spread to biological sites where 
antifungal drug concentration could be higher and therefore maintain the resistant 
phenotype permanently. 
 The resistant phenotype registered for both groups of C. krusei strains is 
associated to multiple resistance mechanisms, being efflux activity one of the most 
common mechanism as it has already been described in other studies [16, 242, 264]. 
This hypothesis is corroborated by the results obtained with the efflux pump inhibitor, 
since a synergistic effect was registered in the presence of VRC in both the 
microdilution assay and in the agar disk diffusion assay (table 2 and figure 2). Also, ITC 
resistance among several C. krusei clinical isolates was previously described to be 
mostly associated to efflux pumps activity [242]. However, concerning the resistant C. 
krusei strains induced in vitro, only Ck1D30, Ck8D30 and Ck21D30 presented a significant 
increase in ABCs genes expression. Most probably other not yet described genes 
belonging to the ABC transporter family of proteins are present in these strains 
conferring resistance. For example, were described in C. glabrata three genes 
associated to resistance to azoles: CgCDR1, CgCDR2 and CgSNQ2 and C. krusei is 
more closely related to C. glabrata and Sacharomyces cerevisiae than to C. albicans 
[17, 18, 268, 269]. 
 ERG11 gene sequencing showed some heterozygous alterations already 
described in C. krusei by Ricardo et al, but not directly associated to resistance since 
they were present in both susceptible and resistant strains [264]. Since FLC resistance 
is associated with diminished affinity of the azole to the Erg11p it can be speculated that 
these heterozygous alterations could be associated to fluconazole intrinsic resistance. 
Strain Ck24D30 presented a mutation also described by Ricardo et al, at position 418 bp 
(T C), translating into a TyrHis amino acid change [264]. This strain presented the 
lowest gene expression level for the three genes studied therefore this mutation is 
associated to resistance to VRC. Another curious fact is that in the resistant strains 
Ck21D30, Ck32D30 and Ck42D30, heterozygous non synonymous alterations were present 
at position 418 bp. Since the process of evolution of resistance can occur in a stepwise 
way we can suggest that the occurrence of these alterations could only be a midterm 
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position for a more stable resistant phenotype. These alterations could evolve for 
homozygous nonsynonymous mutations in those strains.  
In the present work we showed a case of development of transient resistance to 
VRC in vivo and in vitro in C. krusei strains from different backgrounds. Despite the 
antifungal concentrations reached in the urine are very low, in this case, it was enough 
to induce resistance. Although, normally candiduria is not considered a serious clinical 
situation it can lead to the development of candidemia. Taken all these facts together, 
candiduria might not be an innocent situation and more attention should be given by the 
physicians to these cases. Also, different resistance mechanisms were found in the 
different strains namely efflux pumps activity and ERG11 gene mutations associated to 
resistance. 
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“Descobrir consiste em olhar para o que todo mundo está vendo e pensar uma coisa diferente”. 
Roger Von Oech; fundador e presidente da empresa americana Creative Think. 1948 - 
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OVERALL DISCUSSION  
 
 Among the genus Candida, C. krusei is one of the less studied species perhaps 
because it is not so commonly found as a cause of human infections. The occurrence of 
candidemia as a result of C. krusei is associated to neutropenia, a very serious 
condition, with very high mortality rates associated [270].  
 The different molecular typing techniques were applied in two distinct situations: 
to corroborate or discard the hypothesis of an outbreak (chapter III) and to confirm the 
acquisition of resistance in vivo since different isolates from the same patient with 
different phenotypes were available (chapter IV). Ideally, a typing method should 
discriminate very closely related isolates to reveal person-to-person strain transmission, 
which is important in the development of strategies to prevent further spread. At the 
same time it must be rapid, inexpensive, highly reproducible, and easy to perform and 
interpret [271, 272]. On the other hand, when consecutive isolates are recovered from 
different biological products of the same patient, the hypothesis that the patient could be 
colonized by one or more strains should be corroborated or excluded by genotyping. 
The different techniques used in this study complemented and corroborated each other, 
undoubtedly confirming or discarding the hypothesis presented throughout the present 
work. Several studies point for a combination of RAPDs with other methods providing 
optimal discrimination [273- 275].  
 In chapter IV two independent clinical cases of candidiasis were presented, 
although with many factors in common: one case of candidemia in a leukemia patient 
submitted to a long period of VRC treatment until his death and a case of candiduria in 
a patient submitted to a kidney transplant and then under treatment with VRC during 20 
days. Although very different in terms of life risk to the patients, both clinical situations 
point for the importance of monitoring the susceptibility profile of clinical isolates 
recovered during an antifungal treatment. In both cases the acquisition of resistance to 
VRC occurred due to the antifungal therapy with VRC. In the case of the leukemia 
patient the initial C. krusei isolates recovered from blood cultures were in permanent 
contact with a higher dose of the antifungal drug in contrast to the isolates recovered 
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from the urine of the kidney transplant patient, since VRC presents low urinary diffusion 
[276]. Indeed, the treatment of candiduria is one of the biggest concerns among 
physicians. Fluconazole is the first line treatment in these cases, since other antifungals 
present either renal toxicity such as amphotericin B or low urinary diffusion such as 
VRC, PSC or the echinocandins. However, when dealing with C. krusei known to be 
intrinsic resistant to FLC, other options had to be administered. Even though low 
concentration was achieved in the urine, it was enough to induce resistance. Another 
interesting fact in the development of resistance to VRC is that although two of the 
patients involved in the outbreak hypothesis (chapter III) - the leukemia patient and a 
patient diagnosed with non-Hodgkin lymphoma - were submitted to antifungal therapy 
with VRC, only C. krusei isolates recovered from the leukemia patient were resistant. 
Only 2 C. krusei isolates were recovered from the patient diagnosed with non-Hodgkin 
lymphoma therefore in this case the antifungal therapy was successful. Taken all these 
facts together, we can discuss the fact that the presence of the antifungal is important 
for the development of resistance but other factors are also involved. For example, Lin 
et al. [277] found that patient exposure to piperacillin-tazobactam and vancomycin was 
more important than exposure to FLC in promoting C. krusei BSI. They suggested that 
these two antibacterial agents may promote skin and gastrointestinal tract colonization 
with C. krusei by altering the normal flora and thereby facilitating the colonization of the 
host by the pathogenic yeast [277]. Many factors that influence the development of 
resistance in vivo are not present in the in vitro assays described, such as: concomitant 
therapies, the underlying disease of the host or the diffusion of the antifungal drug to the 
site of isolation of the C. krusei strains. Besides, it is well known the poor relationship 
between the susceptibility profiles in vivo and in vitro. As a result, in contrast to what 
happened in the case of the patient with the kidney transplant, in the absence of the 
antifungal, the strains still maintained the resistant phenotype in vitro.  
 Another issue that arose from this work was the administration of empirical 
therapies. When C. krusei isolates were first recovered from the patients, some of them 
were receiving FLC. It is widely known the intrinsic resistance of C. krusei to FLC so this 
is an example of the major importance of the rapid identification of clinical isolates. 
Unfortunately, a non-directed antifungal therapy is more common in the clinical practice 
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than we would expect [278-281]. This type of studies should be a wakeup call for the 
physicians to claim for rapid identification methods to obtain results before the 
administration of antimicrobial therapy. A study by Abi- Said et al. found that infections 
caused by C. krusei were strongly associated with FLC prophylaxis among neutropenic 
patients at the M. D. Anderson Cancer Centre (Houston, TX) [282]. Candida BSIs have 
been shown to have some of the highest rates of inappropriate therapy and hospital 
mortality among all etiologic agents examined [41, 42, 283-287]. Overall, the treatment 
of candidemia is often found to be inadequate due to the use of an agent to which the 
organism is resistant, to insufficient dose or duration of treatment, or to the absence of 
any treatment at all [41, 42, 285, 286, 288, 289]. Taken together, the presented results 
in this work and others in the same research area emphasize the plasticity of C. krusei 
with respect to the development of resistance to a broad array of antifungals [221, 242, 
251, 253]. Therefore, along with C. glabrata, C. krusei must be considered an important 
indicator specie that should be monitored for the development of antifungal resistance 
[24, 221].  
 One of the main goals of this work was to uncover the mechanisms of resistance 
present in the resistant C. krusei strains either induced in vivo and in vitro. Some of the 
mechanisms previously described in C. krusei strains were confirmed in the present 
work, namely the existence of efflux pumps proteins that promote the cellular extrusion 
of the antifungal. It was highlighted the role of Abc1p encoded by ABC1 gene in both 
works of chapter IV and conversely to the genes CDR2 in C. albicans or C. glabrata, it 
was established the minor role of ABC2 gene in azole resistance in C. krusei. On the 
other hand, it was described for the first time a new point mutation in ERG11 gene 
associated to resistance in C. krusei. The mutation was described in two of the resistant 
C. krusei strains recovered from the leukaemia patient, therefore from resistant strains 
induced in vivo and in a resistant strain incubated in vitro with very low concentration of 
VRC. These are completely unrelated strains, with different backgrounds, but 
possessing the same mutation.  
One of the major drawbacks in the development of this work was the lack of 
information concerning C. krusei genome, which is already sequenced but not 
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annotated. For example, until now only 3 genes were associated to resistance in C. 
krusei, ABC1, ABC2 and ERG11 and we questioned the role of ABC2 gene in 
resistance. Other genes were already studied in C. krusei such as the transporter 
proteins belonging to the MFS but they were not associated to resistance in C. krusei 
[212]. Moreover, in other Candida species, cis and trans –elements regulating the 
expression of multidrug transporters were described, such as the transcription factor 
CgPdr1p in C. glabrata, which is the main regulator of the genes associated with 
resistance to azoles, CgCDR1, CgCDR2  and CgSNQ2 [290, 268, 269]. FCR1 gene 
was identified as a negative regulator of FLC susceptibility in C. albicans, since its 
deletion resulted in a mutant hyperresistant to FLC [291]. TAC1  (transcriptional 
activator of CDR genes) gene was described as the main mediator of ABC transporters 
conferring azole resistance due to upregulation of the ABC transporters in C. albicans 
[292]. The molecular dissection of the CDR1 and CDR2 promoters identified five distinct 
regulatory elements in C. albicans: the BBE (basal expression element) responsible for 
basal expression, the DRE (drug-responsive element) required for the response to 
drugs such as fluphenazine and oestradiol, two SREs (steroid responsive element) 
involved in the response to steroid hormones and the NRE (negative regulatory 
element) [293-295]. This is just a small example of the genes and regulators described 
in other species of Candida associated to resistance. Most probably, homologues 
genes are present in C. krusei, conferring resistance not only to azoles but also to other 
classes of antifungals that could explain in more detail the intrinsic resistance of C. 
krusei to FLC. For example, the two FLC-inducible ABC transporters CgCdr1p and 
CgPdh1p, whose upregulation is mediated by the transcription factor CgPdr1p, are the 
main cause for the innate FLC resistance of C. glabrata  [296]. 
 
 Some questions remained unanswered at the end of this work and that’s why 
the future perspectives referred at the end of a thesis are the first step to begin a new 
work.
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CONCLUSIONS  
 
With the present work the following achievements were accomplished: 
 
- The work presented in chapter III described a long-lasting colonization by C. krusei, 
which should be taken into account when considering the therapeutic protocols given to 
these patients.  
- Molecular genotyping techniques were crucial for the development of the work 
presented in both chapters III and IV. First, in chapter III we concluded that there was 
no outbreak occurring in the neutropenia unit, only a misfortune coincidence. Second, in 
chapter IV we corroborated two cases of acquisition of resistance in vivo by susceptible 
C. krusei isolates in two different patients, with different underlying diseases, different 
concomitant therapies, and different therapeutic protocols. Therefore, we concluded 
that resistance can arose from a diversity of backgrounds being the treatment with VRC 
the common factor. Each case is unique in the process of acquisition of resistance and 
it is a multifactorial phenomenon. It seems that the presence of the antifungal agent is 
almost sufficient condition but the time of development can be influenced by other 
factors. 
- In chapter III we also highlight the importance of good hygiene measures among 
health care workers not only when dealing with the patients but also concerning the 
surrounding environment as they can be contaminated/colonized.  
- In chapter IV we confirmed efflux as one of the main mechanism of resistance to azole 
drugs, such as VRC, mostly associated to an increase in ABC1 gene expression. We 
concluded that ABC2 gene plays a minor role in antifungal resistance. ERG11 gene 
was associated to a VRC resistant phenotype in two different ways: due to its 
overexpression and the description of a new point mutation in some resistant C. krusei 
strains, never described before.  
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“A ciência nunca resolve um problema sem criar pelo menos outros dez.” 
George Bernard Shaw. Dramaturgo, critico, activista politico.1856-1950. 
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 At the end of this work many questions remained unanswered and other 
questions arose. 
 We would like to corroborate the results obtained concerning the 
mechanisms of resistance to VRC, through the knockout of ABC1 and ABC2 
genes in resistant C. krusei strains. First, we would have to develop a molecular 
tool for gene disruption. A plausible selectable marker would be the C. albicans 
SAT1 gene, which confers resistance to nourseothricin (NRS). Construction of 
homozygous null mutants directly from C. krusei wild-type strains by the use of 
dominant selection markers would eliminate all potential problems related to the 
use of auxotrophic markers. The first steps were given for the accomplishment 
of this task and some preliminary results were already obtained: in solid YPD 
medium containing 300 g/ml of NRS wild type C. krusei strains did not grow up 
to 5 days of incubation. However, one major problem in the development of the 
molecular tool and other molecular studies is the lack of information concerning 
the C. krusei genome.  
 A reverse approach could also be performed. Candida albicans 
susceptible strains with deleted CDR1 and/or CDR2 efflux genes, (DSY 448, 
DSY 653 and DSY 654) available in our laboratory could be complemented with 
C. krusei ABC1 and ABC2 genes, restoring azole resistance in these strains.  
Other genes besides ABCs and ERG11 may be associated to resistance. 
We could also evaluate gene expression of other genes described to be 
associated to resistance, look for mutation in those genes or transcription 
factors.  
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“Os dias prósperos não vêm por acaso; são granjeados como as searas, com muita fadiga e 
com muitos intervalos de desalento” 
Camilo Castelo Branco. Escritor, romancista, cronista, critico, dramaturgo, historiador, poeta e 
tradutor. 1825-1890.  
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Abstract   
  
 The treatment of candiduria is always a concern in the clinical practice, due to 
the low level of antifungal drug reaching the urinary tract. A patient submitted to a 
kidney transplant was diagnosed with candiduria involving C. krusei and treated with 
VRC 200mg/2x day for 20 days.  Five C. krusei isolates recovered from the urine were 
selected: one susceptible before VRC therapy (MIC 0.25 g/ml), two resistant during 
VRC therapy (MIC 4.0 g/ml) and two susceptible after VRC discontinuation (MIC 
0.25 g/ml). Clinical isolates were all genotyped using both intergenic repeat-PCR 
patterns (CKRS-1) and CKTNR microsatellite analysis, confirming their genetic 
relationship. Therefore, we were dealing with a case of development of transient 
resistance in vivo. Based on these results, we intended to corroborate the hypothesis that 
exposure to suboptimal VRC concentrations could lead to VRC resistance. We incubated 
eight independent clinical strains of C. krusei with VRC 0.001 g/ml, during 30 days. 
The MICs to VRC of these strains ranged from 2 to 8 g/ml, corresponding to a resistant 
phenotype. In the presence of VRC and the efflux pump blocker FK506, the susceptible 
phenotype was restored in the microdilution assay and inhibition of growth of all the 
VRC-resistant isolates occurred in the agar disk diffusion  
assay. In order to uncover the mechanisms of resistance to VRC, efflux pumps encoded 
by ABC1 and ABC2 genes and the target enzyme of azoles Erg11p, encoded by ERG11 
gene, were investigated.  ABC1 and ERG11 genes were overexpressed in the clinical 
isolates resistant to VRC and decreased to a basal level of expression in post-therapy 
isolates. The C. krusei strains incubated in vitro with small doses of VRC presented at 
least one of the resistance genes significantly overexpressed, mostly ABC1 and ERG11 
genes and different alterations in ERG11 gene sequence. Interestingly, the strain 
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presenting the lowest level of gene expression associated to resistance genes displayed a 
homozygous nonsynonymous mutation at position 418bp (T C), translating into a 
different aminoacid TyrHis.  
In conclusion, although the effective therapeutic concentration of antifungal 
reaching the bladder is usually low, the acquisition of resistance to antifungal drugs can 
be achieved. The mechanisms of resistance studied in the C. krusei strains resistant 
strains were all present and in some strains complement each other. 
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Introduction  
  
 Candida species appear to be unique in their ability to both colonize and cause 
invasive disease in the urinary tract [1]. Candiduria is defined as a superficial infection 
with Candida spp., therefore does not belong to the group of invasive candidiasis (IC) 
[2-4]. Candiduria is asymptomatic in up to 96% of the patients and it is not considered a 
serious clinical condition [5]. However, it can be problematic in patients admitted to 
intensive care units (ICU) namely, immunocompromised patients with underlying 
serious diseases, in patients with permanent urinary catheters, with diabetes or with 
altered bacterial flora, due to intensive use of broad spectrum antibiotics [5-9]. Candida 
albicans is the most important and commonly isolated yeast among Candida 
speciesfollowed by C. glabrata and C. tropicalis [5, 11-13].  In this non-albicans group, 
C. krusei is not frequently isolated [14]. Colonization and invasion of the urinary tract 
can occur in either an antegrade fashion from the bloodstream or retrograde via the 
urethra and bladder, being the latter the most common route of infection. The presence 
of Candida species in the urine may be due to different clinical conditions: 
pyelonephritis or cystitis, hematogenous seeding of the kidney cortex due to 
disseminated candidiasis or colonization of the bladder, perineum or indwelling urinary 
catheter.  However, there is some concern about candiduria since it can be the spark to 
candidemia in critically ill patients. Also, when fungus ball form, there is a strong 
probability of biofilm formation allowing the persistence of the organism in the host [15]. 
One of the big concerns related to candiduria is the therapeutic decision of the 
physicians [13]. This is probably due to the fact that no diagnostic tools are available to 
readily differentiate between candidal urinary tract infections (UTI), colonization or 
contamination in the ICU setting. The IDSA (Infectious Diseases Society of America) 
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has defined indications for therapy of candiduria in late 2003 in the following groups: 
infants with very low birth weights, patients undergoing genitourinary procedures, 
patients with neutropenia, renal transplant recipients and symptomatic patients. Several 
classes of antifungals are available but none of them is the best suited. Fluconazole 
(FLC) is the first choice as it is excreted unchanged by the kidneys. Ketoconazole and 
itraconazole are poorly excreted in the urine, voriconazole and posaconazole achieve 
minimal urinary excretion, amphotericin B is very nephrotoxic, and all echinocandins 
are associated to extremely poor glomerular filtration or tubular secretion in vivo, as 2–
3% of active drug is eliminated in the urine, resulting in subtherapeutic concentrations in 
the urine [5, 16-18].  
 We describe in this work a case of candiduria by C. krusei in a patient submitted 
to a kidney transplant and under VRC therapy. It was registered the transient acquisition 
of resistance to VRC in vivo. Two major mechanisms associated to azole resistance have 
been described in C. krusei: the presence of efflux pump proteins (Abc1p and Abc2p), 
and a diminished sensitivity of the azole antifungals to the enzyme cytochrome P450 
lanosterol 14-demethylase, Erg11p, encoded by ERG11 gene.  Efflux pump proteins in 
C. krusei belong to the ATP Binding Cassette (ABC) transporter family, encoded by 
ABC1 and ABC2 genes which promote the extrusion of the antifungal drug from the cell, 
reducing the cellular drug accumulation. Candida krusei is intrinsically resistant to FLC 
due to alterations in Erg11p binding site [19, 20]. Recently, one mutation associated to 
resistance was described by our team in ERG11 gene in C. krusei strains resistant to 
VRC at position 418 bp (T C) translating into a TyrHis amino acid change [26]. 
Acquisition of resistance in vivo was replicated in vitro in the presence of very low 
concentrations of VRC. We intended to uncover the mechanisms of resistance that 
developed in C. krusei strains in vitro and in vivo.  
PUBLICATIONS 
 
- 178 - 
Material and Methods 
 
CASE REPORT AND CLINICAL C. KRUSEI STRAINS ISOLATION 
 A 20-year-old woman was hospitalized in December 2003, for acute renal failure 
secondary to rhabdomyolisis, induced by atorvastatine (Tahor®). She presented with a 
probable evolution of a previously undiagnosed chronic renal insufficiency, associated 
with urological malformation and familial hypercholesterolemia. In November 2005, 
renal transplantation was performed and immunosuppressive treatment (tacrolimus, 
mycophenolate mofetil and corticoids) was given. Twelve days after transplantation, 
bacteraemia due to Escherichia coli occurred probably due to a contamination of the 
solution for graft kidney preservation. She was administered ceftriaxone and 
ciprofloxacine. At day 18 of transplantation, she presented with an aneurysm dissection 
of renal artery associated with hematoma. Therefore, the surgeons had to perform 
hypogastric autograft and distal anastomosa in hilus of renal graft, resulting in the 
preservation of the graft. Pre-renal hematoma was progressively resolved with 
antibiotics. At day 25
th
 after transplant, the first episode of candiduria occurred. At day 
44
th
 after transplant, oral FLC 200 mg/day was implemented. However, at day 44 of 
kidney transplantation, FLC stopped and began to take oral VRC 200 mgx2/day, 
prescribed for 20 days mainly for graft preservation (prophylaxis), despite probable low 
urinary diffusion associated with low expected efficacy against candiduria. After 82 days 
of renal transplant she was admitted to the emergency with fever, probable dissecting 
aneurysm of renal artery at CT-scan. Therefore, she was submitted to resection of kidney 
graft and prescribed antibiotics and intravenous AmB 1 mg/kg/day for 3 weeks. Since 
the first episode of C. krusei candiduria several C. krusei isolates were recovered and 
five were selected. The C. krusei isolates recovered before the VRC treatment presented 
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a susceptible phenotype, those recovered during VRC treatment presented a resistant 
phenotype and those isolates recovered after the withdraw of the antifungal turned to a 
susceptible phenotype.  
 
CANDIDA KRUSEI CLINICAL ISOLATES GENOTYPING 
 
All the clinical isolates recovered from the patient submitted to kidney transplant 
were evaluated for their genetic relatedness, in order to confirm whether the patient 
harbored the same C. krusei strain or not during her follow-up.  
 
 Total genomic DNA extraction. The protocol was performed as next described. 
Briefly, C. krusei isolates were cultured in 10 ml of YPD liquid medium, overnight at 
35ºC, 150 rpm, and subsequently collected at room temperature by centrifugation 
(Hettich, Universal 320 R, 1610xg, 10min). Total DNA was extracted using 
phenol:chloroform:isoamyl alcohol 25:24:1 (Sigma-Aldrich, Munich, Germany), 
precipitated with 100% ice-cold ethanol (Applichem, Darmstadt, Germany), and 
redissolved in 200 µl of TE buffer. The DNA was treated with 20 µg of RNase 
(Applichem, Darmstadt, Germany), incubated at 37ºC for 1 h. For final precipitation, 20 
µl of 4 M ammonium acetate, pH 4.8 (Sigma-Aldrich, Munich, Germany) and 600 µl of 
ice-cold 100% ethanol (Applichem, Darmstadt, Germany) were added and samples were 
incubated overnight at – 20ºC. DNA samples were resuspended in TE buffer 1x, 
concentration adjusted to 2.0-2.5 g/l and stored at -20ºC for later use.  
 
Genotyping analysis: (i) PCR CKRS-1 analysis. Amplification was performed on 
10 ng of genomic DNA with primers Arno1 (5’-GCCAACACATACATACCTT-3’) and 
Arno2 (5’-GGTAGGATACTAACCACAGC-3’) as described by Carlotti et al [21]. 
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Reaction were performed in 50-µL mixtures containing with 100 µM of each dNTP 
(dNTPset, MBI Fermentas, Vilnius, Lithuania), 0,2 µM of each primer (Genset SA, 
Paris, France), 1X Buffer and 1,5 U REDTaq-Polymerase
TM
 (Sigma
TM
, St Louis, MO, 
USA).  The amplified fragments were visualized after separation by agarose gel 
electrophoresis with ethidium bromide (0.5µg/mL) staining. PCR amplification  
parameters included an initial denaturation step for 4 min at 92°C, 32 cycles of 
annealing for 30s at 55°C, extension for 2 min at 72°C, and denaturation for 30s at 92°C 
followed by final extension at 72°C for 10 min [21].PCR products were visualized and 
compared for amplification pattern similarities using electrophoresis at 140 V for 4 h on 
a 1% agarose gel, and staining with ethidium bromide solution 0.5 mg/ml (Applichem, 
Darmstadt, Germany). PCR amplification products were analyzed using the Gel Logic 
100 Imaging System Software (Kodak). Three unrelated C. krusei clinical isolates of 
distinct patients were used as a control. 
(ii) Microsatellite CKTNR analysis: Assessment of CKTNR polymorphism was 
performed by fragment size analysis, using primers CKTNR3 and CKTNR5 as described 
by Shemer et al [266]. Primers CKTNR3 was 5’ labelled with 
hexachlorocarboxyfluorescein (HEX). Reaction were performed in 20-µL mixtures 
containing 30 ng of genomic DNA, 200 µM of each dNTP (dNTPset, MBI Fermentas, 
Vilnius, Lithuania), 0,5 µM of each primer (Genset SA, Paris, France), 1X Buffer and 
0,5 U REDTaq-Polymerase
TM
 (Sigma
TM
, St Louis, MO, USA). Amplicons were sized 
using capillary electrophoresis on ABI Prism 3130.  Results were expressed with respect 
of haplotype denomination described by Shemer et al., using C. krusei strain CBS 573 as 
control [22]. 
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IN VITRO GENERATION OF VRC-RESISTANT DERIVATIVES OF C. krusei AFTER VOR 
EXPOSURE 
 Eight independent clinical strains of C. krusei susceptible to VRC were isolated 
from several biological products of different patients with different underlying diseases, 
not submitted to VRC therapy (table 1). The strains were grown in brain-heart infusion 
(BHI) broth medium containing 0.001 g/ml of VRC, with daily subcultures in fresh 
BHI-VRC for 30 days, in order to obtain derivatives resistant to VRC. Briefly, every 24 
h, 1 ml of the culture was suspended into 9 ml of fresh BHI broth medium; every 2 days 
a 10 l loopful of yeast cells was cultured in Sabouraud agar plates to check for culture 
contamination. 
 
SUSCEPTIBILITY TESTING AND EFFECT OF THE EFFLUX BLOCKER FK506 
(TACROLIMUS)  
Voriconazole (Pfizer, Groton, CT), PSC (Schering- Plough; New Jersey, USA)   
and ITC (Sigma Aldrich, Saint-Quentin, France) antifungals stock solutions were 
prepared according to the M27-A3 protocol and M27-S4, the fourth informational 
supplement, by the CLSI and maintained in stock solution at -70°C until use. 
Susceptibility profile of the C. krusei clinical isolates and the strains obtained before 
(D0) and after 30 days (D30) of incubation with VRC were performed for the 
antifungals VRC, PSC and ITC, according to CLSI M27-A3 protocol and M27-S4, the 
fourth informational supplement, by the Clinical Laboratory for Standards Institute 
(CLSI) ) [23, 24]. 
The susceptibility profiles to VRC of the C krusei isolates were in accordance to 
the following MIC values: susceptible whenever MIC < 0.5 µg/ml, susceptible dose 
dependent whenever MIC=1.0 µg/ml and resistant whenever MIC > 2.0 µg/ml. The 
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susceptibility profiles to PSC of the C krusei isolates were in accordance to the 
following MIC values: susceptible whenever MIC < 0.5 µg/ml, susceptible dose 
dependent whenever MIC=1.0 µg/ml and resistant whenever MIC > 2.0 µg/ml.  The 
susceptibility profiles to ITC of the C krusei isolates were in accordance to the following 
MIC values: susceptible whenever MIC < 0.125 µg/ml, susceptible dose dependent 
whenever MIC ranges between 0.25-0.5µg/ml and resistant whenever MIC > 1.0 µg/ml. 
Visual readings were performed after 24h and 48h of incubation, according to the same 
protocols. C. krusei type strain ATCC 6258 from the American Type Culture Collection 
was used as control, as recommended [23, 24]. 
 
Microdilution Assay: The reversion of multidrug resistance was described in 
different types of cells, including Candida spp when in the presence of antifungals 
azoles and FK506 (Tacrolimus), a blocker of ATP dependent efflux pumps [25]. 
Therefore, MICs of VRC for C. krusei strains were re- determined, according to CLSI 
M27- A3 and M27-S4 protocols, in the presence of Tacrolimus (FK506) 100 g/ml.  
 
Agar disk diffusion assay: An agar disk diffusion assay was also performed using 
FK506 to corroborate the results obtained with the CLSI protocol: yeast suspensions of 
the distinct resistant strains (0.5 McFarland standard; Densimat, Biomerieux, France), 
were spread each onto YPD agar plates containing VRC at a supra-MIC value, according 
to the MIC value of each strain and without VRC. Blank paper disks, 6mm (BBL, 
Becton Dickinson France S.A.), were impregnated with serial 10-fold dilutions of 
FK506 solutions, ranging from 1000 to 1 g/ml, and with its solvent, dimethyl sulfoxide 
(DMSO, Merck). Dried paper disks were applied onto the inoculated agar plates. A plate 
containing only VRC at the supra-MIC values was used as a control for cell viability for 
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each strain. The agar plates were incubated at 37ºC, and the results were registered after 
24h and 48h.  
 
RESISTANCE GENE EXPRESSION ANALYSIS 
 Total RNA extraction: Selected C. krusei strains were incubated in YPD broth at 
35ºC, 150 rpm, until exponential growth phase; yeast cells were harvested by 
centrifugation at room temperature, (Hettich, Universal 320 R, 1610xg, 5 min), 
immediately frozen in liquid nitrogen. Total RNA was extracted using the hot acid 
phenol method, as described by Köhrer & Domdey [26]. RNA samples were 
resuspended in DNase/ RNase-free water, concentration adjusted to a final concentration 
of 100 ng/l and stored at -70ºC for later use.  
 
Reverse transcriptase PCR (RT-PCR). Two-step real-time PCR reactions were 
performed. Reverse transcriptase reactions were performed as previously described by 
Ricardo et al [27].  The cDNAs were kept at -20ºC until later use. 
 
Quantitative Real-Time PCR (qRT-PCR): ABC1, ABC2 and ERG11 genes were 
amplified using the primer pairs described by Ricardo et al [27]. qRT-PCR reaction 
mixture contained: SensiFAST SYBR No-Rox Mix 1x (Bioline, Taunton, MA, USA), 
primers forward and reverse (ABC1, ABC2, ERG11 0.9 M and ACT1 0.5 M), 2 l of 
cDNA and RNAse-free water, up to a 20 l final reaction volume. MgCl2 was used in 
ABC2 gene reaction mixture at a final concentration of 1mM. All reactions were 
performed in the Mastercycler epgradient Realplex2; parameters were chosen according 
to the manufacturer’s recommendations, including primer annealing temperature, 60ºC. 
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To check for PCR product specificity, a melting curve was established, i. e., temperature 
ranging from 60ºC to 95ºC, for 20 min. 
 
 Data Analysis: A standard curve was inserted, in triplicate, containing serial five-
fold dilutions ranging from 500 ng to 0.8 ng of RNA transcribed to cDNA, as previously 
described by Ricardo et al [27]. The results were analyzed using the program software 
Realplex version 1.5.474, from Eppendorf. Relative target gene expression levels were 
calculated using the software REST 2009 (QIAGEN GmbH, Munich, Germany), being 
the susceptible C. krusei strain the reference sample and each resistant C. krusei strain 
the target sample; ACT1 gene was used to normalize gene expression levels [28]. Target 
genes exhibiting a 2-fold increase in expression and with a p value <0.05 associated 
were considered significantly overexpressed.  
 
STATISTICAL ANALYSIS 
 Result analysis was performed using the software SPSS (Statistical Package for 
Social Sciences) version 19.0. Continuous and paired sample Student's t-test was used to 
analyse significant differences between target gene expression displayed by the distinct 
C. krusei strains; a p value <0.05 was considered statistical significant. 
 
SEQUENCING DATA ANALYSIS OF ERG11 GENE 
 ERG11 gene was sequenced in all selected C. krusei strains in order to 
look for mutations that could be associated to VRC resistance.  
 
Total genomic DNA extraction was performed as previously described in this 
section. 
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 ERG11 gene sequencing reactions and analysis. ERG11 gene (1890 bp) was 
amplified by PCR according to the protocols previously described by Ricardo et al [27]. 
PCR products were treated with ExoSAP-IT (USB Corporation, Cleveland, USA) and 
used as template for the sequencing reactions. Sequencing was performed with a BigDye 
Terminator cycle sequencing ready reaction kit (Applied Biosystems, Carlsbad, USA) 
using primers forward_1, forward_2 and forward_3, as previously described by Ricardo 
et al [264]. DNA products were purified with Sephadex G-50 Fine (GE Healthcare, 
Buckinghamshire, United Kingdom) and sequenced in an ABI Prism 3130 genetic 
analyser (Applied Biosystems, Foster city, USA). Results were analysed with 
Sequencing Analysis software, version 5.2 from Applied Biosystems. The ERG11 gene 
coding sequences of the resistant strains were aligned with the susceptible ERG11 gene 
coding sequence using MUSCLE software/ClustalW [29]. Alignments were analyzed in 
BioEdit software (http://www.mbio.ncsu.edu/BioEdit/bioedit.html)/ ClustalW. 
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Results 
 
C KRUSEI STRAINS DESIGNATION AND SUSCEPTIBILITY PROFILES 
 Five C. krusei clinical isolates were selected and designated according to their 
susceptibility profile and the time of recovery, respectively, during VRC therapy of the 
patient: susceptible isolate CkB.VRC (isolated Before VRC therapy), resistant isolates 
CkD.VRC9 and CkD.VRC16 (isolated During VRC therapy, 9
th
 and 16
th
 day), susceptible 
isolates CkA.VR10 and CkA.VRC18 (isolated After VRC discontinuation, 10
th
 and 18
th
 days). 
Timeline of isolation and susceptibility profiles of each of the C. krusei clinical isolates 
are detailed in figure 1.  
 An increase in the MIC to VRC was registered after 9 days of VRC therapy, the 
isolates achieving a resistant phenotype (CkD.VRC9 and CkD.VRC16); however when the 
drug was withdraw the MIC value turned to the initial values and consequently the initial 
susceptible phenotype (CkA.VR10 and CkA.VRC18). In the case of ITR the first isolates were 
already resistant but in the presence of VRC the MIC value increased even more but 
decreased after its removal. No significant variation occurred in the MIC value of PSC 
which only increased to values related to a SDD phenotype. The hypothesis that the 
same C. krusei strain was colonizing our transplanted patient was corroborated by the 
genotyping technique. All the isolates presented with the same CKRS-1 electrophoretic 
pattern (Fig. 1, panel b) and the same allelic CKNTR microsatellite profile, i.e. profile e-
f/d, according previously described nomenclature [22]. Therefore, all C. krusei isolates 
from our patient were clonal, despite presenting different susceptibility profiles. 
Concerning the strains used for experimental VRC exposure and their in vitro 
induced derivatives, they were randomly numbered and designated according to the day 
of incubation with VRC, i.e., the initial susceptible C. krusei strains obtained before 
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incubation with VRC were referred as D0 and their derivatives after 30 days of 
incubation with VRC were referred as D30. Therefore, we have available the initial 
strains and their derivatives: Ck1D0 and Ck1D30, Ck8D0 and Ck8D30, Ck21D0 and Ck21D30, 
Ck24D0 and Ck24D30, Ck32D0 and Ck32D30, Ck34D0 and Ck34D30, Ck40D0 and Ck40D30, 
Ck42D0 and Ck42D30. Susceptibility profiles are detailed in Table 1. At day 30 of 
incubation with VRC, all the derivatives presented a resistant phenotype to VRC, with 
the MIC values ranging from 2 g/ml to 8g/ml and ITC with the MIC values ranging 
from 1 g/ml to 16 g/ml. 
 
EFFECT OF EFFLUX BLOCKER FK506 (TACROLIMUS)  
 In the microdilution assay the presence of the efflux blocker FK506 lowered the 
MIC values to VRC in all the resistant strains up to 7 fold as it was the case of the C. 
krusei strain Ck21D30. Therefore, all the resistant strains displayed a susceptible 
phenotype in the presence of FK506, with MIC values decreasing from 2-fold up to 7-
fold (Table 2).  
 Concerning the agar disk diffusion assay, all the strains assayed presented growth 
inhibition (although variable in their extent of inhibition) around the disks impregnated 
with the highest concentration of FK506, in the presence of VRC at MIC values. 
Besides, neither FK506 alone nor DMSO, the FK506 solvent, inhibited the growth of the 
C. krusei strains.  
 
RESISTANCE GENE EXPRESSION ANALYSIS  
 ABC1, ABC2 and ERG11 gene expression, for the different groups of strains is 
detailed in Figure 3 (see also figure 1 and table 1).  The gene expression profile of the 
different C. krusei clinical isolates CkD.VRC9 and CkD.VRC16 is in accordance to their 
susceptibility profile, i.e. there is a significant increase in the expression of the resistance 
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genes ABC1 and ERG11: C. krusei strain CkD.VRC9 ABC1 p= 0.007, ERG11 p= 0.001, 
CkD.VRC16 ABC1 p= 0.003, ERG11 p= 0.009. Conversely, ABC2 gene was not 
overexpressed in these strains. The post-therapy susceptible isolates CkA.VR10 and 
CkA.VRC18 presented basal gene expression level for all genes, similar to the reference 
susceptible isolate CkB.VRC, which was in accordance to their susceptibility profile. 
 Interestingly, the C. krusei strains incubated in vitro with small doses of VRC 
presented different gene expression profiles. Except for strains, Ck24D30, Ck34D30 and 
Ck40D30 all the remaining strains D30 present at least one of the resistance genes 
significantly overexpressed when compared to the respective susceptible strain - D0. The 
most remarkable increase in both ABCs genes was registered in Ck21D30 strain, being 
also the strain with the highest MIC value to VRC.     
 
SEQUENCING ANALYSIS OF ERG11 GENE 
 Several ERG11 gene mutations have been previously described to be associated 
to azole resistance in C. albicans [30] therefore, we sequenced C. krusei ERG11 gene in 
the selected strains. 
 Candida krusei strains induced in vitro presented different alterations in ERG11 
gene sequence detailed in table 1. All the susceptible and resistant C. krusei strains from 
both groups of strains presented heterozygous alterations at 642bp (CT) and 1389bp 
(TC), all of them resulting in synonymous SNPs. It should be highlighted the 
homozygous nonsynonymous mutation at position 418 bp (T C), translating a 
different amino acid TyrHis in strain Ck24D30, which presented the lowest level of 
gene expression  associated to the resistance genes studied.  
 
 
PUBLICATIONS 
 
- 189 - 
Discussion 
 Candiduria cases are usually not considered serious clinical situations because 
patient’s life is not at risk. However, the particular case of the patient submitted to a 
kidney transplant triggered our interest once it involved an unusual acquisition of 
resistance as a result of VRC therapy. Management of candiduria involves many 
uncertainties in the indication for antifungal therapy [5, 31]. Therapeutic approaches for 
candiduria are very controversial due to the difficulty in evaluating its clinical 
importance, i.e., if the presence of Candida in the urine reflects infection or colonisation 
[3, 8, 9, 13, 32].  Empirical therapy refers to the treatment of high-risk hosts with 
symptoms of disease, even in the absence of positive cultures or other clinical evidences 
[32]. However, even when antifungal therapy is applied the concentration reaching the 
urinary tract is very small, not reaching an effective dose for treatment. In the clinical 
case presented in this study most certainly the concentration of VRC was not effective 
for the treatment but it was enough to induce resistance in vivo. Also, this clinical case 
was an example of therapeutic errors due to empirical therapy since FLC was 
administrated to the patient when C. krusei strains were responsible for candiduria. One 
possible explanation can be the time of interval between the isolation of the pathogenic 
yeast and its identification. As soon as it was identified the therapy was changed to 
another azole. It was not recommended at the moment to use AMB B due to its 
nephrotoxicity. VRC is not commonly used in this clinical conditions however, since the 
patient was a transplant recipient with a high risk of rejecting the new transplant (the 2
nd
 
transplantation), the aim of the antifungal treatment was first to protect the parenchyma 
of the kidney transplant from Candida infection and then to treat candiduria. According 
to figure 1, the strain colonizing the urinary tract developed a resistant phenotype after 9 
days of VRC therapy and maintained it during the antifungal treatment for additional 7 
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days - CkD.VRC9 and CkD.VRC16, respectively. When VRC treatment was discontinued the 
same strain turned susceptible as shown by the genotyping assays, figure 1 panel (b). We 
can conclude that the C. krusei isolate suffered a selective pressure, developing 
resistance and activitating the efflux pumps. However, when the treatment stopped, 
along with the selective pressure the strain no longer needed to actively maintain the 
efflux activity. Anyway the patient was under a risk situation because the resistant 
strains could spread to biological sites where antifungal drug concentration could be 
higher and therefore maintain the resistant phenotype permanently. 
 The resistant phenotype registered for both groups of C. krusei strains is 
associated to multiple resistance mechanisms, being efflux activity one of the most 
common mechanism as it has already been described in other studies [27, 34, 35]. This 
hypothesis is corroborated by the results obtained with the efflux pump inhibitor, since a 
synergistic effect was registered in the presence of VRC in both the microdilution assay 
and in the agar disk diffusion assay (table 2 and figure 2). Also, ITC resistance among 
several C. krusei clinical isolates was previously described to be mostly associated to 
efflux pumps activity [34]. However, concerning the resistant C. krusei strains induced 
in vitro, only Ck1D30, Ck8D30 and Ck21D30 presented a significant increase in ABCs genes 
expression. Most probably other not yet described genes belonging to the ABC 
transporter family of proteins are present in these strains conferring resistance. For 
example, were described in C. glabrata three genes associated to resistance to azoles: 
CgCDR1, CgCDR2 and CgSNQ2 and C. krusei is more closely related to C. glabrata 
and Sacharomyces cerevisiae than to C. albicans [36-39]. 
 ERG11 gene sequencing showed some heterozygous alterations already 
described in C. krusei by Ricardo et al, but not directly associated to resistance since 
they were present in both susceptible and resistant strains [27]. Since FLC resistance is 
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associated with diminished affinity of the azole to the Erg11p it can be speculated that 
these heterozygous alterations could be associated to fluconazole intrinsic resistance. 
Strain Ck24D30 presented a mutation also described by Ricardo et al, at position 418 bp 
(T C), translating into a TyrHis amino acid change [27]. This strain presented the 
lowest gene expression level for the three genes studied therefore this mutation is 
associated to resistance to VRC. Another curious fact is that in the resistant strains 
Ck21D30, Ck32D30 and Ck42D30, heterozygous non synonymous alterations were present 
at position 418 bp. Since the process of evolution of resistance can occur in a stepwise 
way we can suggest that the occurrence of these alterations could only be a midterm 
position for a more stable resistant phenotype. These alterations could evolve for 
homozygous nonsynonymous mutations in those strains.  
In the present work we showed a case of development of transient resistance to 
VRC in vivo and in vitro in C. krusei strains from different backgrounds. Despite the 
antifungal concentrations reached in the urine are very low, in this case, it was enough to 
induce resistance. Although, normally candiduria is not considered a serious clinical 
situation it can lead to the development of candidemia. Taken all these facts together, 
candiduria might not be an innocent situation and more attention should be given by the 
physicians to these cases. Also, different resistance mechanisms were found in the 
different strains namely efflux pumps activity and ERG11 gene mutations associated to 
resistance. 
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Table 1 – MIC, susceptibility profile, ABC1, ABC2 and ERG11 relative gene 
expression profile and ERG11 gene sequence alterations of C. krusei strains induced 
in vitro. 
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Table 2 - MIC and susceptibility profiles to VRC alone and in combination with 
FK506 of C. krusei strains. 
 
 
Resistance  
VRC MIC (µg/ml)/ susceptibility profile when used with: 
Strains ID No FK506 100 g/ml FK506 
In vivo acquired 
CkD.VRC9 4.0/R 0.125/S 
CkD.VRC16 4.0/R 0.125/S 
In vitro acquired 
(D30 strains) 
Ck1 
2.0/R 0.25/S 
Ck8 
2.0/R 0.06/S 
Ck21 
8.0/R 0.06/S 
Ck24 
4.0/R 1.0/SDD 
Ck32 
2.0/R 0.125/S 
Ck34 4.0/R 0.125/S 
Ck40 
2.0/R 0.06/S 
Ck42 4.0/R 0.25/S 
 
 
 
 
 
 
PUBLICATIONS 
 
- 199 - 
 
 
Figure 1 - In vivo induction of resistance to voriconazole. (a) Timeline of the renal 
transplant procedure, antifungal therapy and C. krusei clinical isolates recovered from 
the kidney transplant patient and their respective susceptibility profile; (b) Genotyping 
of C. krusei clinical isolates. 1- CkB.VRC, 2- CkD.VRC9, 3- CkD.VRC16; 4- CkA.VRC10, 
CkA.VRC18, NRS 1-3 – Non related isolates, M – Molecular weight; (c) Relative gene 
expression profile of ABC1, ABC2 and ERG11 genes for the C. krusei clinical isolates; 
*p < 0.05.  
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Figure 2 - FK506 agar disk diffusion assay: resistant C. krusei strains were grown on 
YPD medium and paper disks impregnated with serial 10-fold dilutions of FK506, 
ranging from 1000 to 1 g/ml (FK506 disks - left column) and DMSO (S1 – 100%, S2 – 
10%) and in the presence of VRC 4 g/ml (VRC 4 µg/ml + FK506 disks- right column). 
(a) C. krusei resistant clinical isolates recovered from the kidney transplant patient; (b) 
C. krusei resistant strains induced in vitro, after incubation with VRC.     
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A 
 
B 
  
Figure 3 - ABC1, ABC2 and ERG11 relative gene expression level in C. krusei 
resistant clinical isolates (A) and resistant in vitro induced strains (B). ABC1, ABC2 
and ERG11 gene expression level was quantified and normalized relative to the 
housekeeping gene, ACT1; relative gene expression level was calculated as a ratio 
between each C. krusei resistant strain and the respective susceptible isolate; * p< 0.05.  
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